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Primary open angle glaucoma (POAG) is the most common form of the prevalent 
neurodegenerative ocular disorder, and mutations in the protein myocilin are closely linked 
to inherited forms of POAG. Instead of secretion from trabecular meshwork (TM) cells to 
the extracellular matrix (ECM) of the TM that regulates fluid flow in the eye, mutant 
myocilin builds up in the endoplasmic reticulum of TM cells. This leads to TM cell death, 
the misregulation of fluid flow, ocular hypertension, and the early onset of the retina 
degeneration associated with glaucoma. Nearly all of the documented disease-causing 
mutations occur in the C-terminal olfactomedin (OLF) domain of myocilin (myoc-OLF).  
While many OLF domain-containing proteins are implicated in disease, the biological 
function(s) of OLF domains are elusive, and, until this work, molecular details of OLF 
domains were also largely unknown.   
Previous data from the lab had indicated that myoc-OLF, like other ECM proteins, 
is stabilized by the addition of Ca2+; however, the myoc-OLF sequence had no predicted 
Ca2+ binding sites. The thermal stabilities of variants representing sites of potential Ca2+ 
ligands were monitored via differential scanning fluorimetry (DSF), and selected variants 
were further characterized by CD, metal analysis, and chelator binding.  A total of 24 
variants of myoc-OLF were analyzed, 18 of which were glaucoma-causing mutations, but 
just three potential Ca2+ ligands emerged. The Ca2+ binding residue, Asp 380, was 
identified. The disease-associated myoc-OLF D380A variant is able to fold, with a melting 
temperature somewhat less than that of wild-type, but was not thermally stabilized by the 
addition of Ca2+. Metal analysis of wild-type myoc-OLF revealed that Ca2+ is present at a 
nearly 1:1 ratio compared to 0.1:1 for the D380A variant, and fluorescence by the Ca2+ 




unfolding. Taken together, these experiments pointed to a novel high affinity Ca2+ binding 
site largely buried within myoc-OLF, which was verified by the myoc-OLF crystal structure.   
The myoc-OLF domain was previously shown in the lab to grow amyloid-like fibrils.  
Analysis of the myoc-OLF sequence with amyloid prediction programs revealed three 
potential amyloidogenic regions. Two of these peptide stretches grew amyloid-like fibrils 
with similar morphologies to those grown by full-length myoc-OLF. The myoc-OLF crystal 
structure revealed that the two peptides that grew fibrils occupied the two inner beta 
strands of opposing blades, whereas the peptide that did not occupied a different region 
of the blade.  
The structure of myoc-OLF was solved by anomalous phasing via 
selenomethionine-incorporated single wavelength anomalous diffraction (SeMet-SAD). 
SeMet substituted myoc-OLF(E396D), a single nucleotide polymorphism (SNP) variant 
that grew superior quality crystals to those of wild-type myoc-OLF, was used for initial 
phasing. Structures of myoc-OLF(E396D) without SeMet and wild-type myoc-OLF, whose 
data set was collected by former PhD student Susan Orwig, were solved via molecular 
replacement. The highest resolution structure, 1.9 Å, was obtained from crystals of myoc-
OLF(E396D). The topology is a new 5-bladed β-propeller covalently tethered by a disulfide 
bond, as predicted biochemically, between two N- and C-terminal cysteine residues 
present in the myoc-OLF domain.  The Ca2+ binding site, involves residues residing on 
three interior beta stands in three separate blades and may stabilize myoc-OLF. A 
previously unknown binding site adjacent to the Ca2+ site is modelled as a Na+ ion. Our 
three solved myoc-OLF domain structures also reveal surface loop conformations that 
have different surface features and accessibility to the Ca2+ site. 
 While propellers are known for having the ability to interact with multiple proteins, 




OLF domain. However structures revealed potential binding regions uncovered by both 
computational solvent mapping and small molecule binding. Of particular interest is an 
interior binding site predicted in all three myoc-OLF structures, and occupied by a glycerol 
molecule in two of the structures. This site has been shown computationally to be able to 
accommodate small molecules similar to glycerol that are in the aqueous humor such as 
lactate and glutamate, which thermally stabilize myoc-OLF similarly to glycerol. On the 
surface, the aforementioned observed loop conformational changes are due to changes 
in the position of a Trp/Tyr pair, revealing different binding regions, and have different 
small molecules bound in two of the structures. This result shows the potential for the 
movement of the Trp/Tyr pair to select for ligand binding or protein-protein interactions. 
The conservation of residues of 1000 OLF domains mapped onto the myoc-OLF structure, 
reveals a stark difference in the surfaces of OLF proteins, despite a highly conserved 
interior cavity. This reveals the possibility that OLF domains have a conserved function 
particularly in the Ca2+-binding region, such as Ca2+ sensing, but varying interacting 
partners. 
Finally, the structure of myoc-OLF has also been utilized to provide insight on the 
relation between disease mutations and misfolding of myoc-OLF. 90% of disease causing 
mutations found in the human population within myoc-OLF fall into three misfolding “hot-
spots”: the hydrophobic region between blades, the Ca2+ environ, and the residues found 
within or stabilizing a long loop that potentially caps solvent access to the interior 
hydrophilic cavity. This long loop harbors several disease causing mutations and a highly 
conserved, previously unknown, cation-π interaction. Mutations predicted to interfere with 
this cation-π interaction have been shown to be very destabilizing. This new knowledge 









 Glaucoma is a group of neurodegenerative diseases of the optic nerve, with 
varying etiologies, that is a leading cause of irreversible blindness1, 2 affecting more than 
60 million people worldwide.3 Vision loss is attributable to the death of retinal ganglion 
cells (RGCs), which carry visual signals from the eye to the brain. Damage to the nerve 
fiber layer surrounding the RGCs leads to nerve cupping and eventual vision loss due to 
RGC death.4 Cupping differentiates glaucoma from other optic neuropathies involving 
RGC death.5 Since glaucoma is often asymptomatic before vision loss occurs, individuals 
with risk factors for glaucoma can be monitored for optic nerve cupping to diagnose 
glaucoma before the death of RGCs and subsequent loss of visual field.1 In the past, 
elevated intraocular pressure (IOP) was included in the definition of glaucoma, however 
the optic neuropathy associated with glaucoma can exist in individuals considered to have 
normal IOP, less than 21 mm Hg, termed normal tension glaucoma (NTG).2 For treatment 
of both NTG and high IOP glaucoma patients, lowering IOP was shown to be beneficial 
for slowing visual field loss.6 This approach has proven useful at reducing the loss of visual 
field over time, but IOP reduction alone does not completely halt disease progression.7 
  
1.1.1 Types of Glaucoma 
There are many forms of glaucoma, and the heterogeneity of the disease 
increases the difficulty in developing treatments. Glaucoma can be divided based on the 




with OAG being both more common, accounting for approximately 75% of glaucoma 
cases in the population.3 OAG and CAG can both be further divided into primary and 
secondary forms.  Primary closed-angle glaucoma (PCAG) has obstructed outflow of 
aqueous humor (AH), and often corresponding increased IOP, due to pupillary block, 
where the iris is in contact with the trabecular meshwork (TM). While secondary closed-
angle glaucoma (SCAG) has iridocorneal angle closure and obstructed AH outflow due to 
a secondary cause such as inflammation.8 Primary open-angle glaucoma (POAG) is the 
most common form of glaucoma, and refers to disease that presents itself without being 
attributable to other disease, injury or closed iridocorneal angle.8 Secondary open-angle 
glaucoma (SOAG) refers to glaucoma that is due to other causes such as 
Pseudoexfoliation (PEX) syndrome,9 or prolonged use of steroids, which can lead to 
SOAG in about 30% of the population, a form of the disease termed steroid-induced 
glaucoma.10 Finally glaucoma can be further divided based on age of onset into 
congenital, juvenile (for those with onset at less than 35 years of age) and adult onset.  
 
1.1.2 Genetics of Glaucoma 
Similar to the varying etiologies and pathogenesis of glaucoma, the genetics of 
glaucoma are not straightforward. The first, and to date most evidenced, gene associated 
with glaucoma is MYOC, and numerous mutations have been linked with juvenile OAG.11, 
12 Other genes associated with OAG include OPTN and WDR36, which are seen in both 
inherited and sporadic forms of adult onset POAG.12, 13 OPTN is more specifically related 
to NTG with the E50K mutation.14, 15 Inherited genetic susceptibility for glaucoma has been 
found in studies on POAG patient families, with relatives of POAG patients 20% more 
likely to develop glaucoma in their lifetime than controls.16 MYOC, OPTN and WDR36 




rs4236601 near Cav1/Cav2 is associated with POAG.17, 18 Over 20 other genes have been 
associated with glaucoma susceptibility including CYP1B1, which is associated with PCG 
(primary congenital glaucoma) and POAG,13 TP53 (tumor protein 53), APOE 
(apolipoprotein), and IL1 α and β (Interleukin-1 α and β), validating the concern that 
glaucoma is due to a complicated mix of genetics and environ.12 
 
1.1.3 Glaucoma and Other Diseases 
 Glaucoma susceptibility has also been linked to patients with Alzheimer’s disease 
(AD) and diabetes. While studies have shown correlation between the diseases, there 
have been conflicting studies showing no increased risk for glaucoma in patients with 
either AD or diabetes.19, 20 Currently since no correlation with AD can be ruled out, and 
since glaucoma has been shown to have similar cellular processes to AD,21 AD may be 
viewed as a risk factor for glaucoma and vice versa.22 While there are conflicting studies 
with diabetes as well, it is better accepted as a risk factor for glaucoma as diabetes 
patients have been repeatedly shown to be more likely to have higher IOP and develop 
glaucoma than non-diabetes patients.20 
 
1.1.4 Aqueous Humor Production, Outflow, Intraocular Pressure and Glaucoma 
 AH is produced in the nonpigmented epithelial cells of the ciliary body in the eye, 
flows from the posterior to anterior segment of the eye, and out through either the 
conventional or uveoscleral pathway (Figure 1.1). AH supplies the nonvascular eye 
tissues, such as the lens and cornea, and maintains the shape of the eye necessary for 
vision. The conventional pathway involves outflow through the TM to the Schlemm’s canal 
(SC) and episcleral vein. In the uveoscleral pathway, AH passes through the ciliary body 




inflow and outflow of AH. Elevated IOP increases outflow through the conventional 
pathway, but has little effect on outflow through the uveoscleral pathway.24 Aging and 
disease affect AH outflow facility.25 In the healthy eye, decreases in both inflow and 
uveoscleral outflow occur in older populations, but the conventional outflow and IOP is 
maintained.26 Glaucoma risk increases with age and elevated IOP,27 and outflow facility is 
impaired in disease, though the exact cause is unknown.25  
 Tissues within the eye change during glaucoma disease progression. Some of 
these changes, such as those of the lamina cribrosa and prelaminar tissues that are 
involved in optic nerve head cupping, can be monitored to track glaucoma progression.28 
Changes in other tissues such as the TM and SC are very similar to changes that occur 
within the eye due to aging, and may offer insight into the source of glaucoma 
pathogenesis, as the TM and SC are involved in regulating outflow of AH in the 
conventional pathway (Figure 1.1). Glaucomatous eyes have been shown to have 
increased extracellular matrix (ECM) stiffness in the TM,29 increased cell stiffness of the 









Figure 1.1 Aqueous humor pathway. Flow of AH within the anterior chamber of the 
eye. a. Inset shows overview of the eye. Reproduced with permission from7. Copyright 
Massachusetts Medical Society. b. Cross section of the anterior chamber of the eye with 





1.2 Myocilin Linked with Glaucoma 
 Myocilin, originally Trabecular Meshwork Inducible Glucocorticoid Response or 
TIGR, was initially linked with steroid induced glaucoma. Prolonged use of steroids was 
shown to increase IOP and cause secondary glaucoma in some patients. The discovery 
of increased myocilin or TIGR expression upon exposure of human TM cells to steroids, 
such as dexamethasone, led to the association of myocilin with steroid glaucoma.32, 33  
The link between myocilin up-regulation by dexamethasone exposure and IOP 
increase is not understood, although myocilin expression is not directly regulated by 




genetic link between myocilin and glaucoma was initially found in a large genetics study 
of a family with juvenile OAG, where the defect was assigned to a gene designated GLC1A 
mapped to chromosome 1q21-1q23.35 Further familial studies verified the link between the 
GLC1A gene and inherited OAG,36 and eventually the gene product was identified and 
named myocilin for its myosin-like domain and its localization to the ciliary rootlet and 
cilium of photoreceptor cells.37  
 
1.2.1 Steroid Induced Glaucoma  
 Steroid use has been shown to cause elevated IOP in a subset of the population, 
and steroid treated mice and cells are used as a model system of glaucoma progression 
due to the changes in the TM with long exposure to steroids.38 There are several genes 
upregulated in the TM upon extended exposure to steroids, but the overexpression of 
myocilin is implicated in the rise of IOP. While the exact link between myocilin expression 
levels and decreased outflow through the TM is not understood, myocilin has been shown 
to be overexpressed in TM cells exposed to glucocorticoids,39 the delay in myocilin 
overexpression is similar to the delay in IOP increase upon exposure to steroids, and 
myocilin expression levels correlate with doses of glucocorticoids required for elevated 
IOP.38 Additionally, myocilin perfused anterior segments showed an increase in IOP, 
whereas eyes treated with denatured myocilin or other proteins such as bovine serum 
albumin showed no IOP increase.40, 41 However myocilin has been shown to be 
upregulated under extended high IOP42 and with mechanical stretch43  pointing to a 







1.2.2 Mutant Myocilin and Glaucoma 
 Over 100 mutations have been documented in myocilin with many implicated in an 
early onset of OAG.44 10-30% of juvenile OAG and 2-4% of all POAG cases are linked 
with myocilin mutations.45 The underlying cause of mutant myocilin-associated glaucoma, 
like steroid induced glaucoma, is not well understood. Several models for mutant myocilin 
pathogenesis have been put forward.  Similar to the overexpression of myocilin due to 
steroid exposure, mutations in myocilin might lead to overexpression of myocilin and 
accumulation in the TM obstructing outflow,46 or mitochondrial membrane disruption.23  
The prevalent mechanism proposed for mutant myocilin pathogenesis is that of a toxic 
gain of function of mutant myocilin aggregates within the endoplasmic reticulum (ER) of 
TM cells that eventually leads to TM cell death and dysregulation of outflow through the 
TM and increased IOP (Figure 1.2).47 Indeed myocilin mutants have lower thermal stability 
than wild type myocilin,48 and have been shown to grow amyloid-like fibrils,49 furthering 
this hypothesis. Myocilin localization to the sheath materials of the corneoscleral 
meshwork and juxtacanalicular tissue may play a role in glaucoma pathogenesis as 
increased sheath materials are seen in glaucomatous eyes.50, 51 While the 
pathophysiology of myocilin glaucoma in both steroid induced and OAG forms is still not 
understood. The study of the role of myocilin in disease progression is also hindered by 





Figure 1.2 Myocilin secretion and accumulation. a. Wild type myocilin is secreted to 
the ECM. b. Mutant myocilin sequesters native myocilin and prevents secretion of both 





1.2.3 Myocilin as a Potential Therapeutic Target for Glaucoma 
Once diagnosed, options to treat glaucoma fall into several classes all of which 
target lowering IOP as a method to slow disease progression.52 IOP is modulated by 
decreasing AH production or increasing outflow though the uveoscleral pathway or the 
conventional pathway. Small molecules used now to treat glaucoma were all originally 
developed for other diseases. Even though drugs are generally applied topically to the 




Myocilin is one of the first identified modifiable drug targets to treat glaucoma. Early 
studies demonstrated that mutant myocilin secretion could be rescued by culturing TM 
cells at a lower temperature,47, 53, 54 presumably because aggregation rates are slowed at 
temperatures below the unfolding temperature of mutant myocilin. Thus far, attempts to 
rescue secretion using small molecules have included both chemical and pharmacological 
chaperone approaches. For the former approach, a series of osmolytes were shown to 
increase thermal stability of mutants to better than wild-type levels in vitro,48, 55 with simple 
compounds, like sucrose, exhibiting the most potent stability enhancement. The chemical 
chaperones TMAO56 and 4-phenylbutyrate (4PBA)57 also improved secretion of mutant 
myocilin; however, the high concentrations needed by chemical chaperones to enhance 
the stability of myocilin limit their usefulness as therapeutics. With no known function for 
myocilin, there is no biochemical assay for the discovery of pharmacological chaperones, 
and secondary assays such as cell secretion and inhibition of aggregation are low-
throughput, making their use as a screening method laborious. One method for a high-
throughput, target-independent stability assay was developed in which myoc-OLF was 
slightly destabilized and subsequent stabilization due to addition of ligand was monitored 
to determine potential scaffolds that bind to myoc-OLF. From this assay, two compounds 
were found that restored wild type thermal stability, inhibited amyloid formation and 
increased secretion.58 Additionally, the recent crystal structure of myoc-OLF, should 
accelerate the discovery of new selective ligands for myocilin with similar properties 








1.3 Myocilin Localization, Function and Characterization 
Myocilin is a 504 amino acid protein that is expressed in several tissues in the eye 
including the TM, retina, iris and ciliary epithelium,60 but is also expressed in non-ocular 
tissues such as the sciatic nerve61 and skeletal muscle.37 Myocilin has been found to be 
localized primarily extracellularly, depending upon the tissue,60 and has been shown to be 
proteolytically cleaved, in a calcium dependent manner, by calpain II into an N-terminal 
domain and a C-terminal olfactomedin (OLF) domain; both the C-terminal OLF domain 
and full length myocilin can be secreted.62 The N-terminal domain contains a leucine 
zipper/coiled-coil region, predicted glycosylation sites33 and is responsible for the 
multimerization of myocilin.33, 63 The C-terminal OLF domain is predominantly β-sheet64 
and harbors ~90% of glaucoma casing mutations found in myocilin.65 OLF domains are 
found in proteins expressed throughout the body, but have no known function, and until 
this work, were of unknown structure.  
 Myocilin has been shown to interact with various ECM structural proteins and likely 
has varied functions outside the cell. The interaction of myocilin and fibronectin has been 
implicated in modulating cell matrix interactions in the TM66 and impairing formation of 
focal adhesions by blocking incorporation of paxillin.67 Myocilin has also been implicated 
in modifying signaling pathways such as cytoskeletal restructuring through a non-
canonical Wnt signaling pathway,68 and inducing cell proliferation and survival of apoptosis 
by affecting the extracellular signal related kinases 1/2  (ERK 1/2)  pathway.69 
Furthermore, as previously mentioned, myocilin may play a role in stress response, as 
mechanical stress43  and elevated IOP42 have been shown to increase myocilin expression 
in the TM. Although myocilin is widely accepted to be a secreted protein, it has also been 
shown to interact with mitochondria in TM cells, astrocytes,70 and microtubules.71 




during retinal development,72 specifically by modulating BCL2L1 expression levels and 
inducing retinal neuron cell death in mice overexpressing myocilin, or reducing retinal 
neuron cell death in myocilin knockout mice. Flotillin-1 is, to date, the only identified 
interacting partner of the OLF domain of myocilin;73 most reported protein-protein 
interacting partners are localized to the N-terminal domain,63, 68, 74, 75 but many of these 
interactions have not been confirmed by other laboratories or further studies. In sum, the 
biological function of myocilin is unclear and an active area of investigation.45 
 
1.3.1 Potential Calcium Binding Site in Myocilin 
 Myocilin is predicted to be localized to various calcium rich cellular regions, initially 
during folding in the ER, as part of its purported role in the mitochondria, or as a secreted 
protein to the ECM where calcium binding is common,76 including that of eye tissues where 
calcium levels are high.77, 78 Most calcium binding motifs contain aspartate or glutamate 
residues to coordinate calcium, and OLF domains have many highly conserved aspartate 
residues. Prior work demonstrating stabilization of the negatively-charged myocilin and 
glycosaminoglycans pointed to a potential role for calcium, or other metal ion, to mediate 
binding.64, 79 Taken together, with the calcium dependent cleavage of myocilin by calpain 
II,62 we tested the hypothesis that myocilin harbors a calcium binding site, or multiple such 
sites, in the OLF domain (see Chapter 2). 
 
1.3.2 Myocilin Amyloid Propensity 
 Glaucoma-associated mutant myocilin has been shown to form intracellular 
aggregates47, 80 and wild type myocilin is also associated with aggregation when 
overexpressed.38 Prior work from the lab demonstrated that the β-sheet rich OLF domain 




destabilize myocilin OLF (myoc-OLF), are folded at room temperature and retain similar 
secondary structure to wild type.48 At physiological temperatures, thermally destabilized 
myocilin mutants are expected to accumulate a population of unfolded protein that should 
be cleared by endoplasmic reticulum associated degradation (ERAD); surprisingly, this is 
not the case for myocilin mutants which instead induce the ER stress response, leading 
to cell death.81, 82  Mutant myocilin can also cause a decrease in wild type myocilin 
secretion as has been shown with other amyloidogenic proteins.83 Consistent with a toxic 
gain of pathogenic function hypothesis for mutant myocilin, the myocilin knockout mice,84 
and individuals with truncated myocilin,85 do not get glaucoma.  
 
 
1.4 Thesis Objectives 
 
1.4.1 The Glaucoma-Associated Olfactomedin Domain of Myocilin is a Novel 
Calcium Binding Protein  
 Since calcium ions are important biological cofactors that play numerous roles in 
ECM proteins, the calcium binding properties of the myoc-OLF domain were examined. 
Our study reveals an unprecedented high affinity calcium-binding site within the myoc-
OLF domain. The calcium ion bound to wild-type OLF remains largely intact throughout 
the purification process. A glaucoma-causing OLF variant, myoc-OLF(D380A), is calcium-
depleted. Key differences in secondary and tertiary structure between myoc-OLF(D380A) 
and wild-type myoc-OLF, as well as limited access to chelators, indicate that the calcium 
binding site is largely buried in the interior of the protein. Analysis of six conserved 
aspartate or glutamate residues and an additional 18 disease-causing variants revealed 




finding expands our knowledge of calcium binding in ECM proteins; provides new clues 
into domain structure, function, and pathogenesis for myocilin; and insights into highly 




1.4.2 Determination of Amyloidogenic Peptide Stretches in the Myocilin 
Olfactomedin Domain 
 Prior work in the lab demonstrated that wild-type and mutated myoc-OLFs can 
form amyloidogenic fibrils in vitro.49 The systematic investigation of experimental 
conditions leading to amyloid formation, including varying salt concentration, mechanical 
rocking, and pH for wild-type, or mutant myocilin yielded two distinct fibril morphologies. 
Assessment of the myoc-OLF sequence with online amyloid prediction servers yielded 
three distinct sequences with amyloid propensity. Two of the three predicted 
amyloidogenic peptide stretches grew fibrils, which matched morphologies seen for the 
OLF domain. These peptides may represent the portions of the myoc-OLF sequence 
responsible for fibril formation. 
 
1.4.3 Structural Characterization of the Myocilin Olfactomedin Domain 
In this chapter, we present the analysis of three crystal structures of the myoc-OLF 
domain. The structures reveal a new addition to the small family of five-bladed β-
propellers. A calcium ion, sodium ion and glycerol molecule were identified within a central 
hydrophilic cavity that is accessible via movements of surface loop residues. Evolutionary 




for possible overlapping and distinctive functional protein–protein or protein–ligand 
interactions across the broader OLF domain family. 
 
1.4.4 Structural Implications for Glaucoma Pathogenesis 
Myocilin glaucoma is a protein folding disorder similar to Alzheimer’s, Parkinson’s 
and Huntington’s diseases.86 While wild-type myoc-OLF is a well-folded monomer, single 
glaucomatous point mutations impair folding to the extent that only insoluble aggregates 
are isolated.48 By mapping familial glaucoma-associated lesions onto the myoc-OLF 
structure, three regions sensitive to aggregation have been identified, with direct 
applicability to differentiating between neutral and disease causing non-synonymous 
mutations documented in the human population worldwide.  The assignment of newly 
discovered mutations as disease causing can be aided by their location within one of the 
three identified regions. 
 
1.4.5 Identification of Ligand Binding Sites in the Myocilin Olfactomedin Domain 
 The functions of myocilin and OLF domains in general remain elusive. The three 
crystal structures of the myoc-OLF domain offer the first opportunity for structural based 
prediction of ligand binding which may offer insight into the functions of myocilin and OLF 
domains. Additionally, the structures offer the first opportunity for in silico drug design to 
potentially treat myocilin glaucoma. The comparison of experimental and computational 





CHAPTER 2  
THE GLAUCOMA-ASSOCIATED OLFACTOMEDIN DOMAIN OF 




 Present at millimolar concentrations, calcium ions play versatile roles in the 
extracellular milieu.87 Extracellular calcium ions are important in maintaining numerous 
cell-cell, cell-matrix, and matrix-matrix interactions, and accordingly, binding sites for 
calcium exist within associated ECM proteins.88 Compared to our understanding of the 
roles of calcium in wound healing and blood coagulation, and in matrices like bone, our 
comprehension of the roles of calcium in tissues of the eye is largely limited. Despite the 
fact that ocular hypertension accompanying the highly prevalent ocular disorder glaucoma 
is treated with calcium channel blockers and adrenergic receptor agonists to affect salt 
concentrations,89 and even though metal ions are recognized important regulatory factors 
in fluid outflow through the TM tissue involved in maintaining IOP,90 details are largely 
missing.  
 Myocilin is a unique component of the TM linked to glaucoma pathogenesis. First, 
myocilin is linked to steroid-induced, secondary forms of glaucoma. Steroid treatment 
increases myocilin expression,91 and high levels of myocilin have been linked to activation 
of the unfolded protein response in Drosophila eyes,92 but the pathogenic mechanism has 
not yet been elucidated.93 Second, mutations in myocilin comprise the strongest genetic 
linkage to POAG, the most prevalent disease subtype. Inherited in an autosomal-dominant 




result in the accumulation of myocilin within human TM cells instead of secretion to the 
TM.45 The scenario presents a toxic gain of function wherein TM cells expressing mutant 
myocilin die and, by an unknown mechanism, lead to an increase in IOP, which brings 
about the premature onset of glaucoma symptoms. Overall, myocilin-associated inherited 
glaucoma falls into a protein conformational disorder; mutant myocilin aggregation may 
be a function of the fact that disease-causing myoc-OLF variants are less stable than their 
wild-type counterpart.48 and/or its ability to form amyloid fibrils.94 
 Paradoxically, in spite of its clear disease relevance, little is known about the 
structure or normal biological function of myocilin in the TM. In studies of full-length 
myocilin, ECM interacting partners such as actin, laminin, fibronectin, and heparan sulfate, 
as well as cell-matrix adhesion properties, have been localized to the N-terminal coiled-
coil, not the OLF domain.75, 79, 95-97 In addition, the explicit function of non-myoc-OLF 
homologs, distributed throughout the body and commonly found in neural tissues, is also 
unknown.98 Other than myocilin, there has been limited functional and molecular 
characterization of other OLF-containing proteins, such as amassin-1, a sea urchin protein 
involved in cell-cell adhesion of coelomocytes,99 gliomedin involved in nerve conduction 
within myelinating fibers,100 and olfacomedin-4, which has recently emerged as a factor in 
a variety of human disorders, including some cancers 101-103 and irritable bowel 
syndrome.104 
 Based on the prevalence of calcium levels measured in ocular tissues 77, 78 like 
other ECM tissues,76 we set out to investigate whether the OLF domain of myocilin harbors 
a calcium-binding site. The presence of numerous highly conserved aspartates among 
OLF domains and interaction of myocilin with negatively charged glycosaminoglycans79 
further suggest a need for such charge stabilization. Although sequence-gazing and 




experimentally identified and characterized an unprecedented, single, high affinity, 
calcium binding site within the OLF domain of myocilin. This site is likely prevalent among 
most other OLF domains. Specific to myocilin, our results suggest new roles in the TM 




2.2.1 Initial identification of Calcium Stabilization in Myocilin Olfactomedin 
  Previous assays of the effects of metal ions on myoc-OLF excluded calcium ions 
due to experimental design.64 Reassessment of myoc-OLF stability with calcium ions in a 
compatible buffer revealed a clear increase in thermal stability over Mg2+ and independent 
of anion, as measured by differential scanning fluorimetry (DSF) (Table 2.1, see Methods), 
a technique that reports ligand binding as an increase in thermal stability.105 This 
phenomenon is observed even in the case of a fully-bound protein when the ligand only 




Table 2.1 Analysis of stabilization of Myoc-OLF by divalent metal ions. 
Sample Tm (°C) ΔTm (°C) 
Myoc-OLF 53.0 ± 0.5 -- 
Myoc-OLF + 10 mM CaCl2 59.6 ± 0.2 6.6 
Myoc-OLF + 10 mM Ca(OAc)2 60.0 ± 0.1 7.0 
Myoc-OLF + 10 mM MgCl2 52.8 ± 0.2 -0.2 
Myoc-OLF + 10 mM Mg(OAc)2 53.6 ± 0.5 0.6 
Myoc-OLF, pH 4.6 48.9 ± 0.1 -- 







2.2.2 Elemental Analysis by Inductively Coupled Plasma Optical Emission 
Spectroscopy 
 Given the fact that the typical purification procedure involves numerous hours of 
contact with buffers containing 1 mM ethylenediaminetetraacetic acid (EDTA) (Kd = 3.2 x 
10-8 M for Ca2+ 107), we expected the as-isolated maltose binding protein-myoc-OLF fusion 
protein (MBP-OLF)  to lack Ca2+. However, elemental analysis by ICP-OES (Table 2.2) 
revealed significant levels of Ca2+. Omission of EDTA from the purification procedure 
yielded nearly stoichiometric values consistent with a single bound Ca2+ to the monomeric 




Table 2.2 Elemental analysis for Ca2+ by ICP-OES. 
Sample Ca: protein (per mole) 
MBP-OLF as-isolated 0.81 
EDTA-free MBP-OLF  0.96 












2.2.3 Release of Calcium upon Unfolding  
 When incubated with Quin-2, a fluorescent ethylene glycol tetraacetic acid (EGTA) 
analog with Kd= 2.9 x 10-9 M,
108 high fluorescence values indicative of Ca2+ release from 





Figure 2.1 Ca2+ binding assay for myoc-OLF and myoc-OLF(D380A). Fluorescence of 












2.2.4 Calcium Binding Monitored by Isothermal Titration Calorimetry 
 To date, we have not been able to prepare a native form of apo myoc-OLF or fully 
reload myoc-OLF; isothermal titration calorimetry using cleaved myoc-OLF reveals only 





Figure 2.2 Calorimetric titration of myoc-OLF with Ca2+. a. Raw data from titration of 
270 µM myoc-OLF with 10 µl aliquots of 5 mM CaCl2 in 20 mM MOPS pH 7.2 at 25 °C. b. 
Plot of integrated heat versus Ca2+/protein molar ratio. Fit to a single binding site indicates 
ratio of 0.1 Ca2+/protein. Additional titrations with different concentrations of myoc-OLF 
and CaCl2, as well as at higher temperature, did not alter this ratio, supporting the 







2.2.5 Mutational Analysis of Carboxylic Acid-Containing Residues as Ligands for 
Calcium Reveals Glaucoma-Associated Aspartate 380  
 To deduce the metal binding residues in myoc-OLF, and in light of the fact that 
there is no enzymatic activity reported for myocilin we tested site-directed myoc-OLF 
mutants for stabilization by Ca2+. A variant that loses its ability to be stabilized by calcium 
is lacking a candidate ligand. A total of six candidate conserved aspartates or glutamates, 
commonly found as ligands to calcium ions in proteins,109 were identified by sequence 
analysis of the myoc-OLF domains from other organisms (Figure 2.3). Of these, Asp 273, 
Asp 378, Asp 384, and Glu 385 were replaced with alanine. Asp 380 was previously 
mutated to alanine, and is also a disease-causing variant.55 The sixth, Asp 490, is removed 
when generating the core-OLF.64 Myoc-OLF(D378A) could only be isolated in an 
aggregated state, and thus stability measurements on the folded monomer could not be 
conducted. The challenge encountered with myoc-OLF(D378A) is somewhat surprising 
given that the equivalent position in the non-myocilin OLF domain of the orthologue 
amassin contains an alanine (Figure 2.3, gi_28453877). Both myoc-OLF(D273A) and 
myoc-OLF(D380A) were isolated as monomers in sufficient quantities and their stabilities 
were found to be unaffected the presence of Ca2+. Due to the low initial stability of the 
D273A variant (Tm = 22 °C), however, we only cautiously implicate Asp 273 as a ligand 
for Ca2+ in myoc-OLF. By contrast, the D380A variant, also a disease-causing residue 
(see below), is a moderately stable protein (Tm = 46 °C) and could be evaluated further. 
In addition to completely ablating stabilization by Ca2+, myoc-OLF(D380A) does not co-
purify with Ca2+, as confirmed by Quin-2 binding (Figure 2.1) and metal analysis (Table 








Consensus SS                        eeeeee     eeeeee        eeee           eeeee        eeeeee  hh 
gi_3065674      228 -LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWRIDT-VGTDVRQVFEYDLIS 305  
gi_62632725     205 ---------QDGPADISGCGDLVWVENPEVHRKADSIAGKYGVWMQDPEAKEPYGPDMVWRIDS-VGSEVRQLFGYENMD 274  
gi_74356501     214 -LKESPSGHPRNEEGGTGCGELVWVGEPITLRTAETITGKYGVWMRDPQATFPYTGETTWRIDT-VGTDIRQVFEYDHIR 291  
gi_47522798     213 -LKESVSGHSGSEEGGSGCGELVWVGEPVTLRTAETITGKYGVWMRDPKATYPYTQETTWRIDT-VGTDIRQVFEYDRIS 290  
gi_15077142     214 -LKENPSGRPRSKEGDKGCGALVWVGEPVTLRTAETIAGKYGVWMRDPKPTHPYTQESTWRIDT-VGTEIRQVFEYSQIS 291  
gi_3845607      227 --LKNQSGHPRSKEGDKGCGVLMWVGEPVTLRTAETITGKYGVWMRDPKPTHPYTQETTWRIDT-VGTGIRQVFEYSQIS 303  
gi_28453877     209 TEDESLFQPWSDFPSQDSCRDIIHVSEPFTVRGVG---NKIGAWFRDPLQDYI----KVYYAPFHNPRLTYQVDRFAHVA 281  
Disease Mutation                      *     *                   *              
 
Consensus SS       hhhh       eeee         eeeee eeeee      eeeee     eeeeee           ee      eeee 
gi_3065674      306 QFMQGYPS---KVHILPRPLESTGAVVYSGSLYFQGAESRTVIRYELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLA 382  
gi_62632725     275 QLTRGFPT---KVLLLPESVESTGATMYKGSLYYQRRLSRTLIRYDLHAESIAARRDLPHAGFHGQFPYSWGGYTDIDLA 351  
gi_74356501     292 QFTQGYPS---KVHVLPRPLESTGAVVYRGSLYFQAAESRTVLRYDLRTETLKAEKEIPGAGYHGQFPYSWGGYTDIDLA 368  
gi_47522798     291 QFAQGYPS---KVHVLPRRLESTGAVVYQGSLYFQGASSRTVIRYELSTETLKAEKEIPGAGYHGQFPYSWGGYTDIDLA 367  
gi_15077142     292 QFEQGYPS---KVHVLPRALESTGAVVYAGSLYFQGAESRTVVRYELDTETVKAEKEIPGAGYHGHFPYAWGGYTDIDLA 368  
gi_3845607      304 QFEQGYPS---KVHVLPQALESTGAVVYAGSLYFQGAESRTVLRYELNTETVKAEKEIPGAGYHGQFPYAWGGYTDIDLA 380  
gi_28453877     282 DFRGGTEYEHRYMLPTNLPAQGPGMVAYNGSLYYHAFQSRQIVRYDLENHTVVTTGEISDADI-----NIRGSPSAIDLA 356  
Disease Mutation                       *                                        *  *         *  *   
 
Consensus SS       ee   eeeeee      eeeeeee     eeeeeee       hheeeeeeeeeeeee       eeeeeee    eeee 
gi_3065674      383 VDEAGLWVIYSTDEAKGAIVLSKLNPENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKT 462  
gi_62632725     352 IDENGLWAIYSTNKAKGAIVISQLDPHNLEVKGTWETKIRKTSVANAFMICGKLYTVASYTSPNTTVNYMFDTATSQGKA 431  
gi_74356501     369 VDEIGLWVIYSTEAAKGAIVLSKLNPETLELEQTWETNIRKQSVANAFIICGTLYTVSSYSSPDATVNFAYDTGTGSSKA 448  
gi_47522798     368 VDETGLWVIYSTEAAKGAIVLSKLNPENLELERTWETNIRKQSVANAFIICGTLYTVSSYSSPEATINFAYDTSTGSSKA 447  
gi_15077142     369 VDESGLWVIYSTEEAKGAIVLSKLNPANLELERTWETNIRKQSVANAFVLCGILYTVSSYSSAHATVNFAYDTKTGTSKT 448  
gi_3845607      381 VDESGLWVIYSTEETRGAIVLSKLNPENLELESTWETNIRKQSVANAFVICGILYTVSSYSSVHATINFAYDTNTGISKT 460  
gi_28453877     357 VDELGLWAIYASVSDQTNTMISRLDPETLDVIETWVAPFPKYQAGSCFMVCGRLYCLSSFFSTDSTVELVYETSSNVFRV 436  
Disease Mutation                                           *  **     *   *         
 
Consensus SS                   eeee  hhh  eeeee  eeeeeeeee 
gi_3065674      463 LTIPFKNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM----------------- 504  
gi_62632725     432 ISVPFKNRYRYNSMVDYNSAKRKLYAWDNYYMVSYSVRLGKQE---------------- 474  
gi_74356501     449 LTVPFKNRYKYSSMIDYNPLERKLFAWDNFNMVSYDIKLSRL----------------- 490  
gi_47522798     448 LTIPFKNRYEYSSMIDYNPLEKKLFAWDNFNMVTYDIRLSRM----------------- 489  
gi_15077142     449 LTIPFTNRYKYSSMIDYNPLERKLFAWDNFNMVTYDIKLLEM----------------- 490  
gi_3845607      461 LTIPFKNRYKYSSMVDYNPLERKLFAWDNFNMVTYDIKLSEM----------------- 502  
gi_28453877     437 IDVLFDIRFGEMMSLKYNPRDQKLYGWDNGHQVVYDLTFDPPARSQLLPTDTNIPLNLQ 495  
Disease Mutation                 *  **                 *  * 
 
Figure 2.3 PROMALS 110 sequence alignment of the OLF domain of myocilins.  From 
human (gi_3065674), zebrafish (gi_62632725), cow (gi_74356501), pig (gi_47522798), 
mouse (gi_15077142) and rat (gi_3845607), as well as (non-myocilin) amassin 
(gi_28453877) from sea urchin. Consensus secondary structure (SS) is depicted above 
the alignment. e = β strand, h = helix. Asterisk indicates location of glaucoma-causing 
mutation examined in this study. Red residues are identical, blue residues similar. 
Highlighted residues are conserved aspartate/glutamate positions subjected to site-








2.2.6 Structural Differences between Apo Myocilin Olfactomedin and Wild-Type 
Myocilin Olfactomedin   
 We next examined structural differences between apo and holo myoc-OLF by 
comparing circular dichroism (CD) spectra of wild-type at pH 7.2 and 4.6, and myoc-
OLF(D380A) at pH 7.2 (CD spectra by Dr. Shannon Hill). Overall, the secondary structural 
features are rather similar, with features of β-sheets at ~215 nm and an unusual feature 
at 232 nm seen by us previously.55, 64 However, myoc-OLF(D380A) has a more 
pronounced feature at 232 nm, similar to wild-type OLF at pH 4.664 (Figure 2.4 a). The 232 
nm signal has been attributed to a change in β-turn secondary structure111 as well as 
exposed tryptophan residues.112 In support of the latter interpretation for myoc-OLF, the 
changes in tertiary structure observed in the aromatic region of myoc-OLF(D380A) nearly 
overlay with wild-type myoc-OLF at pH 4.6 (Figure 2.4 b). Notably, myoc-OLF at pH 4.6 is 
still stabilized by Ca2+ (Table 2.1). In sum, the structural changes in myoc-OLF(D380A) 
that lead to ablation of Ca2+ binding are due to the of the loss of coordination of Asp 380 









Figure 2.4 Structural comparison of myoc-OLF and myoc-OLF(D380A). Comparison 
of a. Secondary structure from far-UV spectra and b. tertiary structure from near UV 
spectra among wild-type myocilin -OLF at pH 7.2 (red), wild-type myoc-OLF at pH 4.6 




2.2.7 Investigation of Calcium Stabilization of 18 Other Disease-Causing Myocilin 
Olfactomedin Variants Reveals No Other Impaired Variants   
 Due to the documented participation of other polar residues or main chain-derived 
carbonyls in Ca2+ binding,109 combined with the glaucoma-relevance of myoc-OLF, we 
looked at the extent of stabilization by Ca2+ by 18 disease-causing OLF mutants (Table 
2.3). With the exception of D380A, all of the disease-causing variants were stabilized by 
+5.7-9.1 °C in the presence of 10 mM Ca2+; wild-type myoc-OLF is stabilized by 6.5 °C. 
Although the extent of stabilization varies somewhat, we were unable to statistically 
correlate initial Tm or position in the amino acid sequence with extent of stabilization given 
a single Ca2+ concentration. Thus, the remaining cryptic Ca2+ coordination sphere likely 
involves some combination of other side chains not yet identified, main chain carbonyls, 

















Table 2.3 Analysis of stabilization of myoc-OLF variants by Ca2+. 
Variant Rationale Tm (°C) 
Tm (°C) + 10 
mM CaCl2 
ΔTm (°C) 




49.7 ±  0.3 57.7 ± 0.1 8.1 
MBP-OLF (G246R) disease causing 42.7 ± 0.2 50.6 ± 0.0 8.1 
MBP-OLF (G252R) disease causing  43.0 ± 0.2 51.5 ± 0.2 8.5 




21.7 ± 0.8 21.1 ± 0.7 -0.6 
MBP-OLF (E323K) disease causing  44.0 ± 0.5 50.3 ± 0.2 6.2 
MBP-OLF (G364V) disease causing  45.0 ± 0.4 51.9 ± 0.1 6.9 
MBP-OLF (G367R) disease causing  42.7 ± 0.1 50.9 ± 0.4 8.1 




N/A N/A N/Ab 
MBP-OLF (D380A) 
carboxylate side 
chain & disease 
causing  








39.7 ± 0.4 49.7 ±  0.3 10 
MBP-OLF (K423E) disease causing  34.2 ± 0.4 43.2 ± 0.1 9.0 
MBP-OLF (V426F) disease causing  41.5 ± 0.1 49.9 ± 0.1 8.4 
MBP-OLF (A427T) disease causing  48.3 ± 0.3 55.1 ± 0.4 6.9 
MBP-OLF (C433R) disease causing  40.4 ± 0.4 49.4 ± 0.5 9.0 
MBP-OLF (Y437H) disease causing  40.3 ± 0.4 48.6 ± 0.2 8.3 
MBP-OLF (I477N) disease causing  37.7 ± 0.8 46.8 ± 0.2 9.1 
MBP-OLF (I477S) disease causing  39.7 ± 0.2 48.2 ± 0.5 8.5 
MBP-OLF (N480K) disease causing  42.4 ± 0.2 48.1 ± 0.1 5.9 
MBP-OLF (P481L) disease causing  45.5 ± 0.4 51.2 ± 0.3 5.7 
MBP-OLF (I499F) disease causing  42.8 ± 0.1 50.4 ± 0.4 7.6 
MBP-OLF (S502P) disease causing  41.0 ± 0.3 49.9 ± 0.2 8.9 
    afrom 64  







2.2.8 Estimation of Calcium Dissociation Constant   
Because a strictly apo wild-type myoc-OLF protein could not be prepared for direct 
calorimetric measurement of calcium binding, we estimated the dissociation constant from 
experimental Tm values obtained by differential scanning calorimetry (DSC) (see Methods, 
experiment completed by Katherine Turnage), which are corroborated by CD (Figure 2.5) 
and DSF (Table 2.3), as well as experimental values for the enthalpy of unfolding and 
change in heat capacity for myoc-OLF (D380A) as a proxy for apo myoc-OLF. These 
values lead to a calculated Kd ~ 1.3 x 10-6 M for Ca2+ in myoc-OLF (Calculations by Dr. 
Raquel Lieberman). Combined with results from CD and inaccessibility to chelators under 






Figure 2.5 Stability comparison of myoc-OLF and myoc-OLF(D380A). CD thermal 
melts for myoc-OLF and myoc-OLF(D380A) in MES pH 6.0, monitored at 215 nm in the 




2.2.9 Prediction of Calcium Binding Motifs in Olfactomedin Domain Family  
 Finally, we broadened our scope beyond myocilin to include other OLF domain 
containing proteins, in order to gain insight into whether calcium binding may be an 
inherent characteristic of such domains. Among myocilin orthologues, D380 is located in 
a well-conserved region of the OLF domain peppered with acidic residues that were 
subjected to mutagenesis in our study (see above). Expansion of sequence analysis to 
include 45 OLF homologs available in ProSite,113 combined with an evolutionary trace,114 
reveals that all but one distant branch harbors an aspartate or glutamate at the equivalent 
position of 380 in myocilin (Figure 2.6). Instead of aspartate, these distant relatives, the 
gliomedins, harbor asparagine, which is unlikely to be a ligand for calcium. Notably, Asp 
273 is highly conserved among the expanded list of OLF domains, with the only outliers 
in the same branch lacking a Asp 380. Asp 378 is far less conserved, being replaced with 
tyrosine, leucine and phenylalanine. Thus, while many variants appear to have a well-
positioned aspartate for calcium binding, additional characterization of other OLF domains 






Figure 2.6 Evolutionary tree for 45 OLF domains. Human myocilin is listed as number 






Figure S2. Evolutionary tree (44) for 45 OLF domains. Human myocilin is listed as number 18. Family 







A novel, high affinity Ca2+ site was identified within the OLF domain of myocilin. 
The myoc-OLF Ca2+ binding site contains an unprecedented motif that includes Asp 380, 
the site of a glaucoma-causing lesion. Of the 23 total myoc-OLF variants we investigated, 
including mutants of conserved aspartate/glutamate residues, as well as disease-causing 
mutants, only two additional candidate ligands emerged. However, neither position could 
be confirmed unambiguously due to the severely impaired biophysical properties of the 
resulting recombinant protein. The combination of low thermal stability of myoc-
OLF(D273A) and high level of conservation of aspartate among orthologues at this 
position underscores the importance of this residue to the integrity of the OLF domain. 
This stability reduction is highly residue-specific, however; myoc-OLF(R272G), the 
adjacent disease variant, is a moderately stable protein that is stabilized by calcium. By 
comparison, while Asp 378 could form part of the prevalent D-X-D Ca2+ binding loop found 
in EF-hands and β-blades, the remaining motif is absent and Asp 378 is not well conserved 
among OLF domains. In addition, Asp 380 is predicted to be located within a β-strand. 
The varied nature of calcium binding sites in proteins, which include not only oxygen-
containing amino acid side chains but also main chain carbonyls, hydroxyl moieties, and 
water molecules for a total coordination number of 6-8,115 may render the remaining Ca2+ 
coordination environment in the myoc-OLF inaccessible by site-directed mutagenesis. 
Indeed, the remaining Ca2+ coordination environment in the myoc-OLF domain remained 
enigmatic until the structure was solved (see Chapter 4). 
 Two of the major proposed functions of Ca2+ binding sites in ECM proteins are the 
enhancement of thermal stability and protection against proteolysis.76 In support of these 
roles, we previously observed resistance of myoc-OLF to protease treatment64 and core-




osteonectin, in which the binding of calcium induces a large conformational change,116 
wild-type and myoc-OLF(D380A) have highly similar structural features. Thus, although 
myoc-OLF is more stable than the D380A mutant to thermal denaturation, calcium is not 
absolutely required for OLF folding.  
The estimated binding affinity of the myoc-OLF calcium site based on available 
thermodynamic parameters is also in line with Ca2+ equilibrium dissociation constants of 
other ECM proteins, which are usually in the micromolar range.88 However, myocilin is 
atypical in that the site is largely inaccessible to the strong chelators EDTA and Quin-2. 
This indicates that metal binding likely occurs upon folding in the calcium-rich ER117 and 
once trafficked to the TM, the myoc-OLF domain should be continually saturated with Ca2+, 
based on experimental measurements of millimolar levels of calcium ions in AH.77, 78  
In addition to conferring stability, Ca2+ sites in ECM proteins play regulatory or 
signaling roles, for example, in response to local calcium ion gradients.88 The emerging 
picture appears true in proteins with a stabilizing, high affinity Ca2+ site, regardless of 
whether Ca2+ is bound within a single protein domain or at the interface between domains. 
Calcium ions may directly facilitate ligand interaction or membrane association, or stabilize 
a particular protein conformation so that it is primed for ligand binding or activated for 
catalysis.87 Full-length myocilin is a modular protein like other ECM proteins, but myocilin 
is unusual in that it has a coiled-coil for oligomerization instead of a repeated domain 
structure within a single polypeptide chain. The OLF domain behaves as a monomer in 
vitro,55, 64 and it has been suggested that the myocilin domain structure brings OLF 
domains in close proximity, albeit in an unknown configuration. Even though all but one73 
of the interacting partners for myocilin identified to date appear to not require the OLF 




For example, in the case of amassin, cell-cell interactions were found to be contingent 
upon the presence of calcium ions.118  
Alternatively, or in addition, myocilin may be sensitive to shear stress and play a 
role in signaling a response to biomechanical stress. Indeed, the anterior chamber of the 
eye, including the sponge-like TM tissue, constantly experiences and responds to 
biomechanical changes as a result of normal fluctuations in fluid flow and activities such 
as blinking and eye rubbing.119 For most individuals, the response is robust throughout 
one’s life, indicative of a highly regulated signaling pathway, although one that is poorly 
understood. For others, prolonged fluid shear stress from AH flow, and/or compression 
and stretching of the TM, and/or aging-related morphological changes, leads to chronically 
elevated IOP, and glaucoma-associated vision loss at the optic nerve.  
In support of this involvement, myocilin mRNA levels have been shown to be 
elevated in response to mechanical stress,43 which includes rearrangements of actin 
filaments.120 Myocilin is proposed to interact with actin via its coiled-coil97 but such 
changes could propagate to strip myoc-OLF of its calcium ion, with two thought-provoking 
fates. First, TM remodeling could arise as a consequence of proteolytic susceptibility upon 
metal depletion or by introducing additional calcium to the TM milieu. Second, apo myocilin 
may be less compact and expose an amyloidogenic region leading to fibril formation, and 
in this way contribute to glaucoma pathogenesis. Steroid treatment may exacerbate one 
or both of these potential roles. Related, myocilin may play a part in the regulation of TM 
calcification. Genes associated with calcification are abundantly expressed in the TM. 
Although the details of calcification and/or prevention in the TM, and their physiological or 
pathological role(s), are still unknown,121 myocilin mutants can alter the expression of 




The new knowledge of a calcium site opens a completely new context in which to 
probe the biological and pathogenic roles of myocilin. Additional characterization of the 
OLF domain in the context of full-length myocilin, calcium fluxes and mechanical stress in 
the TM should yield new functional insights and contribute to our still poor comprehension 




2.4.1 Protein Expression and Purification  
 Myoc-OLF and variants were expressed using a modified pMAL-c4x plasmid 
encoding an N-terminal MBP fusion (New England Biolabs) in Rosetta Gami 2 (DE3) 
pLysS (Novagen) cells, as described previously.55 Cells were grown at 37 °C in Superior 
Broth (US Biological) to an optical density at 600 nm of 0.6-0.8, cooled to 18 °C, induced 
with 0.5 mM isopropyl β-D-thiogalactopyranoside (IPTG) and allowed to grow overnight 
(14-16 hours). Cells were flash frozen with liquid nitrogen, and stored at -80 °C. Cell pellets 
were lysed via French Press after suspension in amylose wash buffer (10 mM KH2PO4 , 
10 mM Na2HPO4, 200 mM NaCl and 1 mM EDTA) containing Roche Complete EDTA-free 
Protease Inhibitor Cocktail. Cellular debris was removed via ultracentrifugation (162,000 
x g for 45 minutes at 4 °C), and the supernatant loaded onto a 20 mL column containing 
high flow amylose resin (New England Biolabs), equilibrated with amylose wash buffer. 
The MBP-OLF fusion protein was eluted using amylose wash buffer supplemented with 
10 mM maltose. Elution fractions were concentrated using Amicon Ultra-15 centrifugal 
filtration devices and loaded onto a Superdex 75 prep grade column (GE Healthcare) 
equilibrated with gel filtration buffer (10 mM KH2PO4, 10 mM Na2HPO4 and 200 mM NaCl, 




and concentrated for further use or for protease cleavage. Cleavage of MBP-OLF was 
accomplished using Factor Xa (New England Biolabs or Roche) incubated for 16-18 hours 
in 50 mM Tris pH 8, 100 mM NaCl, and 5 mM CaCl2 at 37 °C (wild-type) or room 
temperature (variants). Cleaved protein was loaded onto the amylose resin column to 
remove MBP and uncleaved fusion protein. Flow-through fractions containing cleaved 
myoc-OLF and Factor Xa were concentrated and subjected to fractionation by Superdex 
75 size exclusion column chromatography. Fractions containing cleaved, pure, myoc-OLF 
were identified by SDS-PAGE, pooled, and concentrated for further use. 
 
 2.4.2 Olfactomedin Variants 
  Site Directed Mutagenesis was accomplished using the QuickChange II® Site 
Directed Mutagenesis Kit (Stratagene). Primers were designed using PrimerX 
(bioinformatics.org) and synthesized by MWG Operon. Primers for sequences that were 
not published previously are in Table 2.4.48, 55 All mutated plasmid sequences were 
confirmed by DNA sequencing (MWG Operon). Protein expression and purification 
proceeded as above. The structural core of myoc-OLF (core-OLF), which lacks Asp 490, 




Table 2.4 Primers used in this study. 
Myoc-OLF (D273A) 5`-gtgtgtggatgcgagcgcccaagcccacctac 
Myoc-OLF (D378A) 5`-cttggggtggctacacggcgattgacttggctgtggatg 
Myoc-OLF (D384A) 5`-cattgacttggctgtggcggaagcaggcctctggg 







2.4.3 Thermal Stability Assay   
 Changes in thermal stability were assessed by DSF105 as modified by us previously 
for MBP-OLF.55, 64 Briefly, 30 μL reactions containing final concentrations of 1-3 μM myoc-
OLF or MBP-OLF variants were diluted into buffer containing 10 mM Hepes pH 7.5, 200 
mM NaCl, and 5X Sypro Orange dye (Invitrogen). For MBP-OLF variants, 50 mM maltose 
was added to stabilize MBP well beyond the range of OLF.55 Salts (CaCl2, Ca(OAc)2, 
MgCl2, or Mg(OAc)2) were added in the range of 0-25 mM. The mixtures were dispensed 
into 96-well optical plates and sealed with optical film (Applied Biosystems). Sypro Orange 
fluorescence was monitored as a function of temperature in an Applied Biosystems Step 
One Plus RT-PCR with fixed excitation at 480 nm and a ROX 610 nm emission filter. 
Thermal melts were conducted in triplicate on two independent samples from 25 to 95 °C 
(5-95 °C for myoc-OLF(D273A) and myoc-OLF(Y437H)) with 1 °C/min incremental 
increase. Fluorescence data were blank-subtracted, and Boltzmann Sigmoid analysis 
conducted using GraphPad Prism to determine the midway point of unfolding, i.e. the 
melting temperature (Tm).  
 
2.4.4 Fluorescence Calcium Binding Assay 
 Purified proteins were concentrated and rediluted into 10 mM Hepes pH 7.5 three 
times, using aforementioned centrifugal filtration devices. The fluorescence of the 
nanomolar affinity Ca2+ chelator Quin-2108 was then measured under native and 
denaturing123 conditions. Reactions containing 8 μM myoc-OLF or myoc-OLF(D380A), 
150 μM Quin-2 and either 0 or 1.4 M GndHCl in 10 mM Hepes pH 7.5 buffer were added 
to Grenier Bio-One Fluotrac 200 96 half-well plates. Fluorescence was measured on a 




528/20 nm. At least two independent measurements were conducted. Reported 
fluorescence values are blank-subtracted.  
 
2.4.5 Inductively Coupled Plasma Optical Emission Spectroscopy  
 As-isolated MBP-OLF was prepared for ICP-OES as described above, except 
using gel filtration buffer treated with Chelex resin (Sigma). Samples of EDTA-free MBP-
OLF, MBP-OLF(D380A) and MBP were purified as reported except EDTA was omitted 
from amylose wash buffer and gel filtration buffer was chelated with Chelex resin. 
Duplicate independent samples of 74-95 μM protein and buffer blanks were analyzed for 
Ca2+ content at the University of Georgia Center for Applied Isotope Studies. Data were 
blank-subtracted, molar ratios calculated, and averages are reported. Protein 
concentrations for MBP-OLF and MBP-OLF(D380A) were based on the experimental 
molar extinction coefficient at 280 nm of 169,978 M-1cm-1 obtained from total amino acid 
analysis (UC Davis Molecular Structure Facility). 
 
2.4.6 Circular Dichroism 
  Far-UV CD, near-UV CD spectra and CD thermal melts (all completed by Dr. 
Shannon Hill),  were acquired on a Jasco J-810 spectropolarimeter equipped with Neslab 
RTE 111 circulating water bath and a Jasco PTC-4245/15 temperature control system. 
For far-UV spectra, samples included myoc-OLF and myoc-OLF(D380A) spectra in gel 
filtration buffer at pH 7.2. For myoc-OLF at pH 4.6, purified protein was subjected to 3x 
concentration and dilution into 10 mM sodium acetate, 200mM NaCl, pH 4.6 using an 
Amicon ultra 15 centrifugal device. For thermal melts, protein samples were first diluted 
into 10 mM MES pH 6.0 buffer and supplemented with 0 or 1 mM CaCl2 to a final 




samples prepared in pH 6.0 or 7.2 (not shown). Far-UV spectra were acquired at 20 °C 
with 30 averaged scans from 300 to 200 nm at a 500 nm min-1 scan rate, using a 0.1 cm 
cuvette. Far-UV melts were performed in duplicate utilizing a 1 °C min-1 increase in 
temperature from 5 to 95 °C. Ten scans from 300 to 200 nm at a 500 nm min-1 scan rate 
were averaged for each temperature.  Data were blank-subtracted and converted to mean 
residue ellipticity Θ= Mres×Θobs/ 10 ×d ×c, where Mres=112.9 is the mean residue mass 
calculated from the protein sequence; Θobs is the observed ellipticity (degrees) at 
wavelength λ; d is the pathlength (cm); and c is the protein concentration (g/ml). The Tm 
was determined using mean residue ellipticity values recorded at 215 nm via Boltzmann 
Sigmoid analysis using Igor Pro. 
Near-UV CD experiments were conducted with myoc-OLF at pH 7.2, at pH 4.6, 
and myoc-OLF(D380A) at pH 7.2, as above (40 - 50 μM). Scans were measured from 
250 nm to 320 nm at a rate of 50 nm/min and a data pitch of 1 nm using a 0.1 cm 
cuvette. Each measurement was an average of 10 scans, converted to mean residue 
ellipticity as above.  
 
2.4.7 Estimate of Calcium Dissociation Constant  
 The Kd of Ca2+ for myoc-OLF was estimated with the binding constant macro in 
Origin 7 using data from DSC (completed by Katherine Turnage, MicroCal VP-Capillary 
DSC) conducted at 15.4 μM protein concentration in gel filtration buffer. The unfolding 
transitions for both myoc-OLF and myoc-OLF(D380A) are not reversible, but can be fit 
well to a non two-state model (not shown). Data from myoc-OLF(D380A) were used as an 
approximation for apo myoc-OLF (see Results). Relevant parameters: For myoc-OLF Tm 
= 56.3 °C, and for myoc-OLF(D380A), Tm = 51.5 °C, ΔHcal = 8.22 x 104 kcal/mol,  





Determination of Amyloidogenic Peptide Stretches in the 




Mutations in the protein myocilin are linked with POAG, and the vast majority of 
these mutations occur within the C-terminal OLF domain.44 Myoc-OLF mutations are 
thermally destabilized compared to wild type,48 and form cytotoxic aggregates that 
accumulate within the ER of TM cells.47, 80 This aggregation eventually leads to cell death, 
reduced AH outflow and increased IOP, which is a major risk factor for glaucoma.47  The 
pathogenesis of mutant myocilin is not well understood, as ERAD should clear the ER of 
misfolded proteins. Instead, mutant myocilin interacts aberrantly with resident ER 
chaperones preventing clearance by the proteasome.124 The aggregation of myocilin, not 
the lack of secretion, appears to play a role in glaucoma pathogenesis, as myocilin 
knockout mice84 and individuals with truncated myocilin85 do not get glaucoma. This points 
to a toxic gain of function mechanism for pathogenesis associated with aggregation of 
myocilin mutants. Accordingly, similar to other amyloidogenic proteins, mutant myocilin 
can decrease wild type myocilin secretion.83   
Systematic characterization of myoc-OLF fibrillization revealed that wild type 
myoc-OLF is well-folded and does not readily fibrilize unless partially unfolded either by 
temperature elevated above body temperature (42 °C) or lowered pH, and fully denaturing 
myocilin yields nonspecific aggregation.125 Disease-associated mutants of myoc-OLF, 




and fibrilize readily at 36 °C (Figure 3.1).125 Two distinct fibril morphologies, curvilinear 
and circular, are formed by wild type myoc-OLF at elevated temperature depending upon 
the presence of salt (Figure 3.2).125  Of the three disease causing myoc-OLF mutations 
studied, A427T and I499F adopt the curvilinear fibrils and D380A forms circular fibrils.125 
Since myoc-OLF only grows fibrils when partially unfolded, we hypothesized that certain 
peptide stretches may exist within the myoc-OLF sequence that, upon exposure with 





Figure 3.1 Structural properties and amyloid fibril growth of native and mutant 
myoc-OLF. a. CD spectra of variants, Wild type (WT) myoc-OLF, disease mutants A427T, 
I499F and D380A myoc-OLF and non-disease polymorphism K398R. b. Tertiary CD 
spectra variants. c.Thioflavin T (ThT) fluorescence of variants. (Spectra and fluorescence 







Figure 3.2 Myoc-OLF fibril growth with and without salt. a. Myoc-OLF fibril growth at 
42 °C monitored by ThT fluorescence in the presence and absence of salt. Corresponding 
Atomic Force Microscopy (AFM) of fibrils formed in the absence (b) and presence (c) of 










3.2.1 Initial Amyloid Prediction in the Olfactomedin Domain of Myocilin  
 To identify any stretches within myoc-OLF that have high amyloid propensity, full 
length myoc-OLF was submitted to four online amyloid prediction servers, Waltz126, 
PASTA127, Amyl_Pred128 and TANGO129. These servers yielded 3 consensus peptide 
stretches of high amyloid propensity (Figure 3.3), G326AVVYSGSLYFQ (P1), 
G387LWVIYSTDEAKGAIVLSK (P2), and V426ANAFIICGTLYTVSSY (P3). P3 was the 
highest predicted stretch followed by P1; P2 exhibited the lowest amyloid propensity 
















Figure 3.4 Amyloid propensity of selected peptides.  Amyloid prediction by the listed 




3.2.2 Peptide Fibril Growth  
 Both P1 and P3 grew fibrils at 500 µM when incubated at 36 °C for 20 hours, as 
monitored by ThT fluorescence (Figure 3.5). P2, however, did not grow fibrils at 500 µM 
when incubated at 36 °C (Figure 3.5), even when incubated for over 72 hours (Figure 
3.6).  AFM performed by Dr. Shannon Hill, was used to visualize fibril formation. P1 grew 





Figure 3.5 Peptide growth. a. Peptide growth monitored by ThT fluorescence. b. AFM of 






Figure 3.6 Peptide 2 growth. a. P2 growth at 36 °C monitored by ThT fluorescence. b. 








3.2.3 Seeding of Full Length Myocilin Olfactomedin by Peptide Fibrils 
 The ability of pre-formed P1 and P3 fibrils to template fibril growth of full length 
myoc-OLF was examined next. Several conditions were tested for both P1 and P3.  At 42 
°C and pH 7.2 with salt, neither peptide was able to seed full length myoc-OLF when tested 
as both as-grown fibrils (data not shown) or sonicated fibrils (Figure 3.7 a and b).  
Conditions used previously to grow curvilinear fibrils of the OLF protein with two 
dimensional (2D) rocking at 37 °C and pH 7.2 with salt125 were tested next. In this case, 
sonicated P1 fibrils were able to increase the rate of myoc-OLF aggregation (Figure 3.7c), 
but P3 fibrils had no effect (Figure 3.7d). When the temperature was increased to 40 °C, 
however, sonicated pre-formed fibrils of both P1 and P3 were able to increase myoc-OLF 
aggregation (Figure 3.7 e).  Even though peptide fibrils were able to seed full length myoc-
OLF aggregation under certain conditions and ThT fluorescence increased, AFM imaging 
revealed that the resultant fibrils did not replicate the curvilinear or circular morphology, 













Figure 3.7 Seeding of myoc-OLF with peptide fibrils.  Full length myoc-OLF seeded by 
P1 (a) or P3 (b) at 42 °C, pH 7.2. Full length myoc-OLF seeded by P1 (c) or P3 (d) at 37 
°C, pH 7.2, with 2D rocking. e. Seeding of full length myoc-OLF by P1 (red) or P3 (blue) 








 While the prediction servers were not in full agreement with the amyloidogenic 
stretches within myoc-OLF, composite scores of the program outputs allowed for the 
selection of three peptides with high prediction (Figure 3.4). Two of the three peptides 
grew ThT positive fibrils with differing morphologies. P1 grew curvilinear fibrils similar to 
that of myoc-OLF in the absence of salt and the disease causing mutants A427T and 
I499F.125 Peptide 2 did not grow fibrils. Possibly the middle sequence of TDEAKG that has 
no secondary structure predicted and no amyloid propensity plays a role in preventing 
fibril formation for Peptide 2. P3 grew circular fibrils similar to myoc-OLF in the presence 
of salt and the disease causing mutant D380A.125 The circular fibrils seen by P3 and myoc-
OLF are different from the fibrils of hallmark amyloids such as Aβ. There are a few potential 
reasons for this odd morphology. Possibly the sequence of P3 yields a more flexible fibril 
core or has a kinked structure leading to the curving fibrils.  The presence of an internal 
Cys in P3 may contribute to its unique morphology. This Cys is involved in a disulfide bond 
in myoc-OLF, which may alter the unfolding pathway exposing this region. P3 was also 
predicted to have antiparallel β-strands by the amyloid prediction sever PASTA, 127 
whereas P1 was predicted to be parallel. This could possibly be responsible for the 
different morphologies.  The similar morphologies formed by the two peptide stretches 
and full length myoc-OLF point to the possibility that these two sequences are responsible 
for amyloid formation, although other amyloidogenic peptides may exist in myocilin. 
Further studies to assess the potential role of these amyloid structures in myocilin 








3.4.1 Selection and Synthesis of Peptides 
 Peptides were selected based on output from four aggregation propensity 
prediciton servers. The full length sequence of myoc-OLF was submitted to Waltz126, 
PASTA127, Amyl_Pred128 and TANGO.129 The output from each program was normalized 
in order to allow for additive scoring, and the propensity for each amino acid was evaluated 
and stretches of 6 or more amino acids in length and predictions by two or more programs 
were chosen for study, yielding Peptides 1, 2, and 3. Peptides were synthesized by Celtek 
Peptides (Nashville, TN), with Peptides 1 and 2 at >95% purity and P3 desalted.   
 
3.4.2 Peptide Fibrillization Assays 
Peptides were diluted to 5 mg mL-1 stock solutions in DMSO, to remove any 
aggregation due to lyophilization, and stored at room temperature. Fibrils were diluted to 
500 µM for fibrillization assays in 10 mM Na2HPO4/KH2PO4, 200 mM NaCl (pH 7.2), and 
10 µM ThT. Peptide fibril growth at 36 °C was monitored on a Shimadzu RF-530/PC 
spectrofluorophotometer using a 200 µL low-head space cell (Starna 26.50LHS-Q-
10/Z15). An excitation wavelength of 440 nm and an emission range of 450–600 nm (slit 
width 3 nm for both) was used.  ThT fluorescence at 485 nm was background subtracted 
with buffer containing 10 µM ThT and plotted versus time for final curves.  
 
3.4.3 Peptide Seeding Assays  
 Peptide seeds were formed by the same method as in the fibrillization assays.  
Myoc-OLF was expressed and purified as previously described (see Chapter 2 Methods). 




conducted using a Biotek Synergy microplate reader.  The 440-nm excitation filter and a 
485-nm emission filter were used to monitor ThT fluorescence. 150 µL samples of 30 µM 
peptide seed and 30 µM myoc-OLF in 10 mM Na2HPO4/KH2PO4, 200 mM NaCl (pH 7.2), 
and 10 µM ThT were prepared in microcentrifuge tubes and transferred to a Grenier 96 
well microplate. Plates were sealed with clear MicroAmp PCR film from Applied 
Biosystems. Measurements at 42 °C or 40 °C were recorded every 10 min, and ThT 
fluorescence at 485 nm was background subtracted with buffer containing 10 µM ThT and 
plotted versus time for final curves. For the 2D rocker assays, 2 mLs of 30 µM peptide 
seed and 30 µM myoc-OLF in 10 mM Na2HPO4/KH2PO4, and 200 mM NaCl (pH 7.2) were 
placed in a 5 mL centrifuge tube and rocked at 37 °C. 100 µL samples were taken at 
various time points over ~120 hours, 10 µM ThT was added, and their fluorescence 











The OLF domain, first identified in its relation to a protein involved in olfactory 
chemoreception in bullfrogs more than 20 years ago,130, 131 is recognized as a large 
domain family (PFAM: PF02191) comprising seven phylogenetic branches.132 OLFs 
characterized to date are found largely as part of extracellular proteins118, 131, 133-135 in 
multicellular organisms. They are implicated in an expansive and growing number of 
human disorders including a host of cancers,98 inflammatory bowel disorder,136 defense 
against infection,137 attention deficit hyperactivity disorder138 and childhood obesity,139 
among others. 
Myocilin, the first to be associated with disease and the best studied OLF domain-
containing protein, is one of the few veritable disease-modifying drug targets for 
glaucoma,45 the second leading cause of blindness worldwide.140 Nonsynonymous lesions 
localized almost exclusively to its OLF domain account for ∼3–10% of POAG cases.45 The 
leading proposed pathogenic mechanism involves a gain of toxic function, namely 
aggregation, in the ER of TM cells, causing eventual cell death and leading to reduced TM 
associated fluid outflow and accelerated onset of ocular hypertension. Although the ER 
chaperone machinery should be capable of efficient degradation of such mutant proteins, 
there appears to be an aberrant interaction between mutant myocilin and chaperones that 




Reported here are three crystal structures of myoc-OLF, revealing a new addition 
to the five-bladed β-propeller structural protein class. Evolutionary considerations indicate 
that OLF domains share a common scaffold but likely interact with distinct surface binding 
partners. This work offers new insight into and lays the groundwork for understanding 




4.2.1 Crystallization of the Myocilin Olfactomedin Domain 
 Crystals of wild type myoc-OLF subjected to in situ proteolysis were grown by 
Katherine Turnage in a solution of 3% PEG 3000, 39% PEG 200, and 100 mM MES, pH 
6.0. The crystals diffracted to 2.0 Å resolution and a complete data set at 2.3 Å resolution 
was collected in March of 2010 by Dr. Susan Orwig. Molecular replacement using a 
predicted structural homolog was unsuccessful, as were attempts with de novo phasing 
through traditional methods such as multiple isomorphous replacement (MIR) or 
anomalous scattering such as single wavelength anomalous diffraction (SAD) and multi-
wavelength anomalous dispersion (MAD) (see Appendix). Attempts to improve 
crystallization included optimization of the wild type myoc-OLF crystals by variations in 
temperature, variations in pH of buffers and buffer composition, and variation of PEG size 
and concentration. 
Heavy metal incorporation into wild type myoc-OLF was abandoned after higher 
quality crystals were grown with single nucleotide polymorphism variants (SNPs) E396D 
(rs61730975), K398R (rs56314834) and the double SNP E396D/K398R. Crystal 
conditions were optimized from the original wild type myoc-OLF condition and initial hits 




The K398R and E396D/K398R crystals were never improved beyond stacked plates, so 
further optimization focused on the E396D crystals, which were more singular, though still 
stacked plates. An optimized solution of 32% PEG 400, 5% PEG 3000 and 50 mM 
CAPSO, pH 9.5 provided reproducible singular crystals of the myoc-OLF(E396D) SNP, 
and a complete data set at 1.9 Å resolution was collected for myoc-OLF(E396D). Heavy 
metal soaks of the myoc-OLF E396D crystals were attempted in order to solve 
experimental phases via MIR or SAD/MAD (See Appendix A). Incorporation of Zn2+ and 
Hg2+ were initially promising for SAD, but was not successful due to pseudomerohedral 
twinning of the myoc-OLF E396D crystals, and the Rfree value could not be improved below 
0.39 at 2.7 Å resolution, even after several hundred rounds of refinement. After successful 
incorporation of selenomethionine (SeMet) in myoc-OLF(E396D) (see Methods) 
experimental phases were solved via SAD. A new crystal form without pathologies was 
identified using SeMet myoc-OLF(E396D), identified from the Hampton Index HT screen, 
and optimized crystals grew in a new condition of 19% PEG 3350, 0.1M Bis–Tris pH 6 and 
0.1M magnesium formate. A complete data set at 2.09 Å resolution, with an average 
anomalous signal of 1.5, was used to solve experimental phases. Molecular replacement 
was then used to obtain the high resolution structure at 1.9 Å resolution of native myoc-
OLF(E396D) (myoc-OLF(E396D)I222) and the 2.1 Å resolution structure of wild-type myoc-


















Data collection    
   Wavelength 0.979370 1.000000 1.033160 
   Space group P1211 I222 I222 
   Cell dimensions    
      a, b, c (Å) 49.48, 50.56, 
50.54 
68.88, 86.65, 87.44 68.66, 85.82, 
88.44 
      α,β,γ ()  90, 97.27, 90 90, 90, 90 90, 90, 90 
   Resolution (Å) 19.6  - 2.09 
 (2.17  - 2.09) 
19.79  - 1.9  
(1.97  - 1.9) 
19.78  - 2.15  
(2.23  - 2.15) 
   Rmerge 0.1174 (0.4071) 0.0884 (0.4386) 0.1025 (0.4144) 
   I/σI 25.23 (5.15) 15.52 (4.21) 15.54 (5.47) 
   Completeness (%) 97.22 (71.65) 99.98 (100.00) 99.93 (99.93) 
   Redundancy 13.9 (5.5) 6.2 (6.3) 7.3 (7.4) 
    
Refinement    
   Resolution (Å) 19.6  - 2.09 19.79  - 1.9  19.78  - 2.15 
   No. reflections 200752 (5952) 130265 (12954) 106349 (10383) 
   Rwork/ Rfree 0.1782/0.2014  0.1724 /0.2098 0.1906/0.2284 
   No. atoms    
       Protein 2079 2072 2065 
       Ligand/ion 36 40 66 
       Water 244 304 135 
   B-factors    
       Protein 11.10 21.10 22.90 
       Ligand/ion 20.10 37.10 32.50 
       Water 28.50 37.30 31.10 
   R.m.s deviations    
       Bond lengths (Å)  0.005 0.005 0.005 
       Bond angles () 0.83 0.78 0.67 
   Ramachandran 
favored      
  and additional 
allowed (%) 







4.2.2 Overall Architecture of the Myocilin Olfactomedin Domain 
 The final models for each of the three myoc-OLF crystal structures include 
residues 244–502 (numbering scheme for full-length myocilin). The N-terminal 16 residues 
of myoc-OLF, which complete the C-terminal fragment of myocilin reported upon 
proteolytic cleavage in cell culture,62 are not visible in the structures, likely because they 
are part of a linker between the OLF domain and N-terminal regions of full-length myocilin. 
The OLF domain is an ∼40 Å diameter by ∼30 Å high β-propeller with five blades, each 
composed of four antiparallel β-strands (Figure 4.1), arranged radially around a central 
water-filled cavity ∼11 Å in diameter (Figure 4.2)  
Compared with other known propellers of varying blade number,141 the blades in 
OLF are notably asymmetric (see also comparison of five-bladed propellers below). Nearly 
half of the toroid-shaped molecule is occupied by Blades D and E. Discontinuous Strands 
D-18/D-18b and E-21/E-21b in the myoc-OLF(E396D) structures (Figure 4.1a) appear as 
single continuous strands in the wild-type myoc-OLF structure (not shown). The electron 
density in this region is well defined in all structures, but for clarity, in the subsequent 
descriptions, it is referred to the blades as labeled in Figure 4.1 for the highest resolution 
structure, that of myoc-OLF(E396D)I222. Other structural features include several helical 
turns and a short α-helix. The α-helix resides between myoc-OLF Strands A-5 and A-6, 
and packs against the E–A blade interface (Figure 4.1a). Despite the lack of sequence 
similarity in this region (Figure 4.3) the α-helix is predicted by secondary structure 
prediction algorithms and is likely a general feature of the OLF domain.  
Two features of OLF stabilize the propeller in a closed circular conformation. First, 
extensive interactions from the sequentially discontinuous two outer strands of Blade E, 
Strands E-1 to E-2 and E-21 (Figure 4.1c), form the propeller feature colloquially termed 




of the propeller (Figure 4.1b), between Cys 245 at the N-terminus of the visible structural 
domain prior to the start of E-1, and Cys 433, located within Loop D-15/D-16 between the 
internal two strands of Blade D. A similar disulfide bond is seen in four-bladed 
propellers.142, 143 but not five-bladed propeller structures. The disulfide bond is likely 
present in most OLF domains, as the C-terminal Cys is highly conserved, and in sequence 
alignments (Figure 4.3) there is typically an N-terminal cysteine near the equivalent 
position of myoc-OLF Cys 245.  
Nearly half of the residues are found within well-ordered loops above and below 
the propeller (Figures 4.1 and 4.4a), with minor differences among the solved structures 
(Figure 4.4 a). The longest loop is composed of residues 360–379 (Figure 4.1d), connects 
Strands B-10 and C-11, and caps the top entrance to the central cavity (Figure 4.2). 
Although no global changes are observed among our structures, Loop B-10/C-11 appears 
to serve as a gate for access to the central cavity via the positioning of the side chains of 
myoc-OLF Trp 373, which resides on Loop B-10/C-11, and Tyr 442, which resides on Loop 
D-16/D-17. In total, three states were captured that are not attributable to crystal contacts 
(Figure 4.4a and b). The side chain of myoc-OLF residue Trp 373 is visible in two 
conformations in the structures, one pointed into the central cavity and the other out 
towards the solvent. The ‘open’ conformation, seen in the wild-type myoc-OLF structure, 
has Trp 373 and Tyr 442 pointing outward towards the bulk solvent, with a polyethylene 
glycol (PEG) molecule bound just beneath the loop at the top of the cavity entrance. In the 
‘semi open’ conformation, seen in myoc-OLF(E396D)I222, Trp 373 is nestled inward, but 
Tyr 442 on the opposite loop still points toward the solvent. This shift enlarges a small 
surface cavity where a bound glycerol was identified in a position distinct from the 
aforementioned PEG. Such PEG and glycerol molecules found fortuitously in the 




the ‘closed’ state is represented by myoc-OLF(E396D)P21, whereby the position of the 
indole ring of Trp 373 is replaced with the phenol side chain of Tyr 442. This shifts the Tyr-
containing loop into an inward conformation significantly different from that seen in the 






Figure 4.1 Structural features of the OLF domain. a. Top and side view of 
representative myoc-OLF propeller. Blades A–E with corresponding numbered strands, 
listed according to myoc-OLF(E396D)I222 structure. b. Internal calcium-binding site and 
disulfide bond at bottom face. c. Molecular clasp region. d.Loop B-10/C-11, comprising 
residues 360–379. Dashed lines represent relevant stabilizing interactions. Coloring: N 







Figure 4.2 Hydrophilic cavity in myoc-OLF. Side view overlay of wild-type (cyan) and 
myocilin OLF(E396D) (red) structures showing overall sequestration of central cavity. 






Figure 4.3 Multiple sequence alignment of representative divergent OLF 
superfamily members. Secondary structure and numbering scheme presented for myoc-
OLF above the alignment. Annotation: arrows and helices represent β-strands and α-
helices, respectively. Strands are numbered as in Figure 4.1 and in text. T: turn; boxed 
and bolded residues: similar; white residues with black background: identical; c: cysteine 






Figure 4.4 Myoc-OLF molecular surface. a. Superposition of wild-type myoc-OLF and 
two myoc-OLF(E396D) structures. Yellow, β-strand; red, α-helix or turn; green, loop. 
Zoomed regions highlight where loop structures differ b. Top face surface representation 
and open–closed Loop B-10/C-11 snapshots observed crystallographically. Cartoon 
representations of boxed region appear below each surface representation as well as 
observed ligands in the corresponding structure (PEG or glycerol, red) with final 2Fo − Fc 












4.2.3 Central Cavity Metal Ion and Other Identified Ligand-Binding Sites 
 Within the central hydrophilic cavity of myoc-OLF, below the aforementioned 
gating loops, resides the calcium ion identified previously by metal analysis (see Chapter 
2).145 The ion was modeled into a 25σ peak in the Fo− Fc difference electron density map 
present after initial model building. The heptacoordinate Ca2+ is ligated by the side chains 
of Asp 380, Asn 428 and Asp 478, all in a monodentate fashion, as well as the carbonyl 
backbones of Ala 429 and Ile 477, and two water molecules (Figure 3a). The structure 
confirms Asp 380, the only previously identified Ca2+ ligand (see Chapter 2).145 The ligand 
environment in myoc-OLF is typical for Ca2+,146 but not in a documented Ca2+ binding motif. 
Consistent with the previous finding that the apo disease variant D380A is a moderately 
stable protein,145 the internal position of the myoc-OLF Ca2+ ion appears as an ionic tether 
for Blades C, D and E (Figure 4.1a) to confer stability. Adjacent to the Ca2+ site, at a 
distance of ∼3.4 Å deeper into the cavity toward the bottom face, a second major Fo − Fc 
difference electron density peak was identified (Figure 4.5a). In our structures, based on 
final refined metal–ligand distances,147 this density is modeled as a Na+ ion coordinated 
by Asp 380 and Asp 478, as well as the carbonyl backbone of Leu 381 and a water 
molecule (Figure 4.5a). Lastly, within the hydrophilic cavity in both closed and semi-open 
states of myoc-OLF(E396D), a glycerol molecule is bound, in the region between Strands 
A-3 and B-7 above the Ca2+ site (Figure 4.5b). Glycerol was not introduced during 





Figure 4.5 Details of the hydrophilic cavity. a. Ca2+ site and coordination details. Final  
2Fo−Fc electron density (blue) is contoured at 1.5σ and difference Fo − Fc density (green) 
depicting crystallographic Na+ site is contoured at 3σ (see text). Distances are listed in Å. 
b. View of observed glycerol located in the internal hydrophilic cavity, with final 2Fo − Fc 









4.2.4 Comparison to Known Five-Bladed Beta-Propellers 
 Myoc-OLF is distinct from the four different proteins with known five-bladed 
propeller folds (Figure 4.6) with root mean squared deviations greater than  3 Å, consistent 
with sequence analyses that confirm OLF domains are not phylogenetically related to 
these propellers (less than 5-9% identity scattered throughout the sequence, not shown). 
Five-bladed propellers are primarily associated with glycosyl hydrolase or 
cyclotransferase activity; other five-bladed propellers include a human apyrase148 and the 
highly symmetric founding member, tachylectin-2, which binds carbohydrates.141  The five 
tachylectin-2 binding sites, located between connecting segments of one sheet and the 
outer two strands of a second adjacent sheet,149 are absent in OLF (Figure 4.6a) 
Superposition of myoc-OLF with arabinase150 or glutaminyl cyclase151 reveals that the only 
potential catalytic residue is the unlikely myoc-OLF Ca2+ ligand Asp 380 (Figure 4.6 b,c). 
While glutaminyl cyclase harbors a Ca2+ binding site, this ion is not part of the glutaminyl 
cyclase active site;151 arabinase has a His-ligated Cl− ion ∼3 Å away with no obvious 
relation to the myoc-OLF Ca2+ site. The surface substrate-binding cleft of arabinase is 
likewise not observed in OLF and clashes with Loop B-10/ C-11 (Figure 4.6b). Similar 
differences with apyrase are observed (Figure 4.6d). In sum, the OLF domain expands 
the diversity of sequentially unrelated β-propellers141 and is a new representative template 
for five-bladed propellers. However, as such, the ligand binding and active sites of these 







Figure 4.6 Comparison of myoc-OLF with known 5-bladed propellers. a. T. tridentatus 
tacylectin superposition with myoc-OLF. The ligand-binding motif is not present in myoc-
OLF. b. C. japonicus arabinase; central cavity Cl- ion, located 3 Å from the myoc-OLF Ca2+ 
ion (purple ball), is omitted for clarity. Left, cartoon representation of superposition. Middle, 
zoom into arabinase active site, with active site residues in stick representation, with 
closest myoc-OLF residues highlighted. Right, substrate (magenta) binding mode, based 
on the catalytically inactive mutant (PDB ID 1GYE). c. X. campestris glutaminyl cyclase; 
central cavity Ca2+ overlays with that of myoc-OLF, and its closest coordination residue is 
glutaminyl cyclase residue Glu 175. Left, cartoon representation of superposition. Right, 
zoom into glutaminyl cyclase active site, with closest myoc-OLF residues highlighted. d. 
H. sapiens apyrase; central cavity Ca2+ ion, location 4 Å from myoc-OLF Ca2+ ion, omitted 
for clarity. Left: cartoon representation for superposition. Right, substrate (magenta) 
binding mode of apyrase, with closest myoc-OLF residues to those stabilizing ligand in 
apyrase labeled and side chains presented as sticks. Purple, myoc-OLF; yellow, other 5-




4.2.5 Surface Electrostatics of Myocilin Olfactomedin  
 Inspection of the electrostatic surface potential (Figure 4.7a) correlates with the 
predicted pI ∼5. The top surface of myoc-OLF contains several charged regions. There is 
a cluster of five positively charged surface Lys and Arg residues, in the loops connecting 
D-18/E-19 and E-20/E-21. A second positively charged surface on this face is in the loop 
that connects Strand C-14/D-15, which exposes two adjacent Lys/Arg residues at the 
helical turn. The main acidic patch on the top surface is formed by loops of Blade B, 
including those that connect to Blades A and C. At the bottom face is another acidic 
surface composed largely of loop residues from Blades C and D. 
 
4.2.6 Evolutionarily Conserved and Divergent Features of Olfactomedin Domains 
To gain better insight into the implications of the observed structural features of 
myoc-OLF on the OLF domain family as a whole, the evolutionary trace152 of 1000 OLF 
domain sequences was mapped onto the OLF structure (Figure 4.7b), revealing regions 
of conserved and divergent features of OLF domains. Spatially clustered, highly 
conserved residues define regions with a high likelihood of functional significance.152 
Interestingly, the interior of OLF contains a high density of conserved residues, including 
Blade C and its loops, the interior strands of Blade D, the central cavity metal ion and 
ligand-binding sites, as well as near the site of a bound PEG at the bottom face (see 
Chapter 6). A major conserved feature revealed by this analysis is a cation–π interaction 
involving Tyr 371 within Loop B-10/C-11 and Lys 423 on Loop C-14/D-15 (Figure 4.7c). 
Cation–π interactions are important for molecular recognition and other biochemical 




the opposite end of the spectrum, the OLF surface clearly exhibits the highest degree of 




Figure 4.7 Surface electrostatics and evolutionary analysis. a. Electrostatic surfaces 
of myoc-OLF in three orientations. The surface potential is colored negative (red, −5 
kT/e−) to positive (blue, +5 kT/e−). b. Results of evolutionary trace mapped onto myoc-
OLF structure highlighting regions of highest and lowest conservation. Range of 
conservation depicted as rainbow.154 c. Details of highly conserved cation–π interaction in 
two orientations. Dashed lines indicate stabilizing interactions spanning 2.4–3.5Å. Color 





OLF domains are broadly involved in development and implicated in a host of 
human ailments, but molecular details of their biological activities and corresponding 
dysfunction in a variety of contexts remain active areas of investigation. Clarification of 
structure-(dys)function relationships continues to grow in importance as the biological 
reach of OLF domain-containing proteins expands in the context of the interactome.155-158 
The discovery that the OLF domain possesses a propeller fold falls in line with the existing 
and complex functional picture. Propellers are generally known for their ability to 
orchestrate multiple signaling events across diverse pathways and have a broad portfolio 
of interacting partners (see, for example RACK1159), both intracellularly and 
extracellularly.160 Evolutionary trace reveals convergent and divergent features of OLFs 
that could not be inferred simply from sequence alignments and homology considerations. 
Available evidence from our structures suggests that the central cavity of the OLF domain 
possesses a common ligand-binding site. Access to the central cavity appears gated in 
myoc-OLF at the top face where exogenous small molecules appear in our structures. In 
support of the solvent accessibility of the internal hydrophilic core of myoc-OLF, glycerol, 
only introduced during cryoprotection of myoc-OLF(E396D) crystals, is seen within the 
central cavity even when the structure reveals the closed Loop B-10/C-11 conformation. 
Entrance to the internal cavity could come from the observed movement of Trp 373 or via 
other loop motions on the top or bottom face that have not yet been detected. Furthermore, 
though prior metal analysis of myoc-OLF clearly identified a single stable ion within a 
chelator-resistant site,145 we cannot rule out the possibility that the crystallographic Na+ 
site is a labile site for Ca2+. A secondary Ca2+ site could enable OLFs to be responsive to 
calcium release or other extracellular function,161 or, in appropriate orthologues, 




of the OLF domain to facilitate higher order protein–protein interactions or complex 
formation. Additional structures of OLF domains from different subfamilies will be valuable 
in expanding our appreciation of the structural and surface divergence of the OLF domain 
family. Analysis of the structures further indicates the possibility of enzymatic function for 
the OLF domain is remote. Known five-bladed β-propeller enzymes have their active sites 
at the top face of the propeller near the central cavity. While there is noted overlap of the 
highly conserved myoc-OLF Asp 380 residue with that of a catalytic aspartate of 
arabinase, it is an unlikely nucleophile. Asp 380 is bound to the Ca2+ and Na+ ions as well 
as provides stabilization to and proper positioning of Tyr 371 of the cation–π interaction. 
Removal of Asp 380 as a Ca2+ ligand by its replacement with disease-associated Ala 
yields a destabilized apo protein48, 145 that readily aggregates in physiological buffers at 
37°C.125 The remaining active site residues associated with hydrolysis in other five-bladed 
propellers are Thr residues in myoc-OLF, which are not commonly associated with 
catalysis.162 Major conformational changes in surface loops would be further required at 
the top face to create a binding pocket of sufficient size and depth to accommodate a 
small molecule substrate. Though it is possible to envision such motion, myoc-OLF 
variants that are expected to modulate the strength of the cation–π interaction are 
destabilized, suggesting that significant stabilization energy would need to be 
compensated upon such hypothetical substrate binding. The remaining loops other than 
B-10/C-11 are rather short and likewise may not be reconfigurable. Without candidate 
catalytic residues or a clear substrate-binding pocket, there is no obvious chemical 
reaction to propose and test.  
In sum, the availability of OLF structures substantially advances our ability to 
interpret current data and design further experiments on function and dysfunction of the 




interactions with other biological small molecules and/or binding partners. In the 
hydrophilic cavity, the binding entity is likely similar among OLFs. At the OLF surface, the 
lack of sequence conservation among subfamilies suggest dissimilar interactions and thus 
function. While the specific functions, ligands and binding partners for OLF domains will 
likely continue to be a challenging long-term experimental pursuit, atomic-detail structural 





4.4.1 Protein Expression and Purification  
Wild-type myoc-OLF and myoc-OLF(E396D) were expressed and purified as 
described previously in Chapter 2. SeMet-substituted myoc-OLF(E396D) was produced 
by expression of the corresponding MBP-OLF(E396D) fusion protein48 in the auxotrophic 
T7 Express Crystal E. coli cell line (New England Biolabs). Individual colonies were 
inoculated into 10 mL starter cultures, grown in Superior Broth (US Biological) overnight 
at 37°C, further diluted into 1 L of Superior Broth and shaken at 200 rpm at 37 °C until an 
OD600 = 2.0 was reached. Cells were then pelleted by centrifugation and resuspended in 
pre-warmed M9 minimal media supplemented with 0.4% glucose, 1 mM MgSO4, 0.1 mM 
CaCl2 and 0.0002% ferric ammonium citrate, but lacking methionine or SeMet. Cells were 
allowed to shake at 37°C for 2.5 h to deplete any remaining methionine. Fifty micrograms 
per milliliter of L-SeMet (Sigma) were added to the cell growth media, and the temperature 
was dropped to 18°C. After 1 h, protein expression was induced with 0.5 mM IPTG, and 
cells were allowed to grow overnight. Cells were pelleted, lysed and purified as described 




of Superior Broth cell culture. Incorporation of SeMet was confirmed by using a Bruker S2 
Picofox instrument.  
 
4.4.2 Crystallization, Data Collection and Structure Determination  
Purified SeMet-substituted myoc-OLF(E3396D)P21 was concentrated to 10 mg/ml, 
and crystals grown by the hanging drop method by equilibration against a solution 
containing 19% PEG 3350, 0.1M Bis–Tris pH 6 and 0.1M magnesium formate. WT myoc-
OLF (10 mg/ml, 50 mM HEPES, pH 7.5, supplemented with 0.36 mg/ml subtilisin A) grew 
crystals by equilibration against a reservoir solution containing 5% PEG 3000, 39% PEG 
200, 100 mM MES, pH 6.0, and crystals of myoc-OLF(E396D)I222 (10 mg/ml in 10 mM 
HEPES, pH 7.5) were grown from 32% PEG 400, 5% PEG 3000 and 50 mM CAPSO, pH 
9.5. Crystals of myoc-OLF(E396D)I222 and myoc-OLF(E396D)P21 were cryo-cooled in a 
solution containing the respective reservoir solution supplemented with 5% glycerol and 
20% PEG 200. The wild-type myoc-OLF crystals were cooled from mother liquor directly. 
Diffraction data were collected at the Advanced Photon Source, Argonne National Labs 
utilizing the The National Institute of General Medical Sciences and National Cancer 
Institute (GM/CA-CAT) 23-ID beamline (wild-type myoc-OLF) and Southeast Regional 
Collaborative Access Team (SER-CAT) 22-ID beamline (myoc-OLF(E396D)). Data were 
processed using XDS/XSCALE.163 The initial structure was solved by single wavelength 
Se anomalous phasing using AutoSol164  for the SeMet incorporated myoc-
OLF(E396D)P21, (mean anomalous difference in units of estimated standard deviation > 1 
across all resolution bins in processed dataset, phasing figure of merit = 0.5) and the other 
two (wild-type myoc-OLF, high-resolution myoc-OLF(E396D)I222) by molecular 
replacement using Phaser,165 using a model generated from experimental phasing. The 




modified from the PEG 400 entry from HicUP database.167 For wild-type myoc-OLF and 
myoc-OLF(E396D)I222, the pseudomerohedral twinning operator identified using Xtriage
168 
was incorporated in the refinement algorithm. Structures have been deposited to the 
protein databank with PDB codes 4WXQ, 4WXS and 4WXU.  
 
4.4.3 Structure Analysis  
Comparison to known structures in the PDB was enabled using DALI169, crystal 
contact analysis using PDBePISA,170 metal coordination analysis conducted using 
FINDSITE171 and MetalS(3),172 and structural alignments using SSM.173 Alignment in 
Figure 4.4 was prepared using PROMALS3D174 and rendered in ESPript.175 Electrostatic 
surface was calculated using PDB2PQR176  and APBS,177 and figures generated in PyMOL 
(www.pymol.org), using the default secondary structure assignment settings. Evolutionary 
trace was conducted using default parameters except for increasing the number of OLF 












 Evidence to date indicates that myocilin glaucoma is a protein folding disorder 
similar to Alzheimer’s, Parkinson’s and Huntington’s diseases.86 While wild-type myoc-
OLF is a well-folded monomer, single glaucomatous point mutations, such as P370L, can 
be sufficient to impair folding to the extent that only insoluble aggregates are isolated.48 
More generally, thermal stabilities of folded, disease-associated variants, measured by 
the Tm, are statistically correlated with the age the associated patients were diagnosed 
with glaucoma.48  Mutations in myocilin related to disease range from those of wild type 
like stability, such as A427T whose reported age of onset is 73 years of age, to the 
thermally destabilized Y437H whose earliest reported age of onset is 8 years of age.48  At 
physiological temperatures, thermally destabilized myocilin mutants could accumulate a 
population of unfolded protein, however these unfolded proteins should be cleared by 
ERAD. Myocilin mutants instead induce the ER stress response, and lead to cell death.81, 
82 Likely in part due to aberrant interactions with glucose regulated protein (GRP) 94, which 
has been shown to interact irreversibly with mutant myocilin, to prevent ERAD 
clearance.124  
 The difficulty encountered by ERAD to clear mutated full-length myocilin from the 
ER may be due to amyloid aggregation of mutant myoc-OLF. Myoc-OLF aggregates 




large-diameter circular species (see Chapter 3).125 These morphologies are similar to 
aggregates formed by two well-conserved peptide stretches within myoc-OLF, P1 
(G326AVVYSGSLYFQ) and P3 (V426ANAFIICGTLYTVSSY), respectively (see Chapter 
3).25 Mutant myoc-OLF more readily forms amyloid-like aggregates than wild type,125 and 
mutant myocilin can also cause a decrease in wild type myocilin secretion as has been 
shown with other amyloidogenic proteins.83 Consistent with a toxic gain of pathogenic 
function hypothesis for mutant myocilin, myocilin knockout mice, 84 and individuals with 
truncated myocilin, 85 do not get glaucoma. The myoc-OLF structure provides the first 





5.2.1 Locations of Familial Glaucoma Variants and Identification of Misfolding 
Trigger Zones 
 Analysis of the locations of 21 myoc-OLF variants with Mendelian inheritance 
patterns in affected families or in selected groups of juvenile/early onset glaucoma 
patients, whose pathogenicity has been correlated quantitatively with thermal stability and 
aggregation propensity in cells and in vitro,47, 48, 53-55 and three non-disease-associated 
SNPs, reveals three distinct destabilizing regions—(i) the core hydrophobic β-sheet belt 
including the molecular clasp, (ii) Loop B-10/C-11 and cation–π interaction, and (iii) Ca2+ 
environs (Table 5.1). The largest number of variants is found within the core β-sheet belt 
of the propeller (Table 5.1), particularly those variants with the lowest Tm, i.e. the most 
destabilized, such as W286R and I477N/S,48, 55 where side chain alterations would disrupt 




substitutions overall appear better tolerated, is the molecular clasp (see Chapter 4, Figure 
4.1c). Such variants, namely moderate variants G246R, G252R, R272G, N480K, I499F 
and S502P, affect the tethering of the strands and/or alignment of the disulfide bond in 
this region. The C433R mutation abrogates disulfide bond formation. Interestingly, 
however, the effect of C433R on stability is not more drastic than that of Y437H,48 the 
variant used in myocilin glaucoma mouse models,80, 178 both are highly conserved residues 
within OLF domains (see Chapter 4, Figure 4.3). In the case of Tyr 437, a water-mediated 
side chain interaction stabilizes the region near the disulfide bond (Figure 5.1). Variants 
involving Loop B-10/C-11, and adjacent cation–π interaction (Table 5.1; also see Chapter 
4, Figures 4.1d and 4.7c), include those that are both moderately stable and severely 
destabilized. The substitution K423E, which would abolish the highly conserved cation–π 
interaction, is one of the most thermally unstable mutations measured to date.55 Similarly, 
although not assessed for stability in vitro due to the fact that it was reported just once, 
Y371D is associated with a teenage onset, severe glaucoma.179 Variants of moderate 
stability V426F and T377M affect the cation–π interaction: Val 426 holds Lys 423 in 
position via main chain interactions, and the side chain of Lys 423 interacts with the main 
chain carbonyl of Thr 377 (see Chapter 4, Figure 4.7c). The side chain of Thr 377 also 
forms a hydrogen bonding interaction with the main chain of Tyr 371, which would be lost 
upon substitution to Met (see Chapter 4, Figure 4.7c). P370L, a severe mutant,53, 180 is a 
site that appears to organize nearby residues on Loop B-10/C-11. Curiously, Pro 370 itself 
does not appear to participate directly in regional stabilization (see Chapter 4, Figure 4.1d 
and 4.7c), nor is it highly conserved among non-myocilin OLF domains (see Chapter 4, 
Figure 4.3). Other moderately stable variants include charge inversion mutant E323K, as 
well as G364V and G367R, which may be better tolerated, because these residues are 




substitutions cluster near the Ca2+ coordination sphere (Table 5.1; also see Chapter 4, 
Figure 4.1b and 4.5a). These include I477N/S, whose main chain interaction with Ca2+ 
may be compromised somewhat by the disruption of the β-sheet core but not enough to 
abolish Ca2+ binding, and the moderately stable apo variant D380A,145 which also serves 
to stabilize the side chain of cation–π residue Tyr 371 (see Chapter 4, Figure 4.7c). In this 
region is A427T, identified within a small group of family members of variable glaucoma 
diagnosis,181 and a mild variant from a protein stability and aggregation standpoint.48 The 
substitution likely weakens Ca2+ coordination to Asn 428 and Ala 429; thus, our structure 
supports the initial pathogenic assignment. Notably, neutral polymorphisms 
(http://www.ncbi.nlm.nih. gov/SNP), E352Q (rs61745146), K398R (rs56314834)65, 182 and 
E396D (rs61730975), are located on surface loops, remote from the identified misfolding 
regions (Table 5.1). Similarly, A445V, identified in glaucoma patients,65, 181-184  has a 
reported age of onset of 63 years, beyond the cutoff considered early onset.65, 181   Like 
the SNPs, Ala 445 is located on a remote surface and exhibits wild-type-like stability48 
(Table 5.2). Thus, our analysis would predict that the charge neutral A445V mutation 
would not be prone to misfolding; additional work will be required to strengthen the 
argument for glaucoma causality in associated individuals, for example, via one of the 
alternative mechanisms proposed for myocilin-associated glaucoma including altered 
endocytosis,185 mitochondrial membrane disruption23 or apoptosis due to susceptibility 





Table 5.1 Glaucoma associated lesions correlated with stability and myoc-OLF 
structure.a 
    
Mutation Tm (°C) Structural Location 
I. Familial Mutations 
A. Hydrophobic β-sheet belt (40%) 
G246R 42.5 ± 0.2  
G252R 43.0 ± 0.2 
R272G 41.0 ± 0.3 
W286R N/Ab 
C433R 40.4 ± 0.4 
Y437H 40.3 ± 0.4 
I477N 37.7 ± 0.8 
I477S 39.7 ± 0.2 
N480K 42.4 ± 0.2 
I499F 42.8 ± 0.1 
S502P 41.0 ± 0.3 
 
   
B. Loop B-10/C-11 and cation-π (33%) 
E323K 44.0 ± 0.5 
 
G364V 45.0 ± 0.4 
G367R 42.7 ± 0.1 
P370L N/Ac 
T377M 44.3 ± 0.3 
K423E 34.2 ± 0.4 
V426F 41.5 ± 0.1 
 
   
C. Ca2+ site environs (17%) 
 
D380Ad 46.6 ± 0.3 
A427T 48.3 ± 0.3 




II. Single Nucleotide Polymorphisms  
E352Q 54.8 ±  0.5c Loop B-9/B-10 
E396D 53.1 ±  0.1c Loop C-12/C-13 
K398R 53.8 ±  0.2c Loop C-12/C-13 
a Percentages in each category of (I) reflect those as listed in44. b I477N/S and N480K 
also belong to C. Tm values as reported in
145  except when denoted c, which are reported 
in 48. N/A indicates that no soluble recombinant protein could be isolated for Tm 
measurement. Tm value for wild-type myoc-OLF = 52.2 °C 





Figure 5.1 Interactions of conserved residue Tyr 437 in myoc-OLF. Y437H is the basis 
of the myocilin glaucoma mouse model; this substitution would weaken the hydrogen 







Table 5.2 Reevaluated variants based on location in the myoc-OLF structure. 
 
As listed in44. 
 




A445V 54.2 ± 0.2 Surface Loop Disease SNP 
V329M 49.6 ± 0.4 β-sheet belt SNP Disease 
S425P 40.8 ± 0.3 β-sheet belt SNP Disease 
R422C 52.1 ± 0.1 Surface Loop SNP No Change 
Y473C 54.2 ± 0.1 Surface Loop SNP No Change 
R342K 50.4 ± 0.1 Surface Loop Disease SNP 
T293K 52.9 ± 0.6 Surface Loop Disease SNP 




5.2.2 Structural Location of Peptide Stretches Responsible for Myocilin 
Olfactomedin Fibril Formation 
 The previously identified amyloidogenic peptides P1 and P3 (see Chapter 3) are 
found within the innermost two strands of opposing Blades B (Strands B-7 and B-8) and 
D (Strands D-15 and D-16) (Figure 5.2).  P3 harbors structurally identified Ca2+-binding 






Figure 5.2 Locations of amyloid stretches as identified in myoc-OLF. P1 generates 








5.2.3 Assessment of Population-Based Myocilin Olfactomedin Variants 
For variants identified from large population-based genetic studies, designation as 
pathogenic or neutral polymorphism is complicated by the heterogeneous nature of 
glaucoma and age onset of disease, and is largely dependent on whether the variant is 
identified in control subjects or relatives of an affected person.182 In addition, few of the 
many tens of variants identified through these studies have been biochemically 
characterized for stability and aggregation propensity. Similar to the treatment of A445V 
above, we applied the structural inferences from familial mutations and SNPs to discern 
the likelihood of pathogenicity of an additional ∼60 disease-causing genetic lesions 
identified in such population studies but lacking confirmed protein behavior.44 
Approximately 90% of the annotated disease or SNP variants in myoc-OLF fall within the 
categories described above (Table 5.1). Six outliers were identified with possible 
alternative assignments, however. These proteins were recombinantly expressed and 
purified, and their Tms measured (Table 5.2) as a direct experimental determinant of 
structural deformation, and thus aggregation propensity and disease liability. First, V329M 
has been identified several times in glaucoma patients,65, 187, 188 but is labeled as a likely 
polymorphism, perhaps because Met is the residue found in the zebrafish myocilin 
homolog. Due to its location within a β-sheet, we predicted V329M to be a pathogenic 
variant. The V329M myoc-OLF variant is indeed somewhat thermally destabilized (Table 
5.2), suggesting a mild pathogenic label, similar to the familial A427T variant described 
above, is likely more appropriate. S425P is also assigned as a neutral polymorphism 
variant,182 but we posited S425P would be prone to misfolding and aggregation, and thus 
instead be better characterized as pathogenic. Specifically, the Pro would compromise the 
position of Lys 423, which is involved in the stabilizing cation–π interaction (see Chapter 




mediocre yield of folded protein previously associated with the least stable familial 
variants, even lower than that of Y437H.48 Variants harboring R422C and Y473C,182, 63 
both labeled as neutral polymorphisms, are further away from the aforementioned 
misfolding regions, but it was not clear whether a lone Cys would interfere with proper 
disulfide bond formation upon folding. Both the R422C and Y473C variants are thermally 
indistinguishable from wild type and are likely non-pathogenic, as originally suggested. 
Finally, labeled pathogenic mutation T293K65, 182-184 and T353I65, 187, 189, 190 whose 
pathogenicity is labeled as uncertain44 are remote surface exposed residues unlikely to 
promote misfolding. In agreement with our structure based prediction, these myoc-OLF 
variants are well folded, have wild-type-like stability and are more likely SNPs than 
causative via a misfolding phenotype in glaucoma. 
 
5.3 Discussion 
We identified three structural trigger zones for misfolding—the hydrophobic inner 
blades, Loop B-10/C-11, and the cavity region with Ca2+—where substitutions correlate 
directly with destabilizing variants. Mutations within the categorized regions yield a folded, 
but non-native structure that enhances myoc-OLF fibrillization propensity.125 In addition, 
we were able to shed new light onto a variant of ambiguous pathogenicity, suggest that 
selected mutations thought previously to be neutral polymorphisms are likely pathogenic, 
and identify probable neutral polymorphisms on the surface of myoc-OLF for further 
interrogation. As continued genetic testing of glaucoma patients throughout the world 
reveals new myocilin variants, it will now be possible to integrate such structural 
knowledge to help evaluate whether a patient is diagnosed with glaucoma because of, or 
unrelated to, the myoc-OLF amino acid substitution. Moreover, the structure affords the 




aggregation using rational drug discovery as a new therapeutic direction. No such targeted 
treatment for any glaucoma subtype is currently available; indeed, a new glaucoma drug 
has not been approved in over a decade.191 Knowledge gleaned through continued 
structure-(dys)function studies of myocilin-associated glaucoma can serve as a model to 
understand the molecular significance of identified mutations in other OLF-associated 
disorders138, 139, 192 and adds to our comprehension of propeller protein folding more 
generally. For myocilin and its relation to glaucoma, our results demonstrate how the 
myoc-OLF structure can be used to strengthen or dispute disease causality in identified 
mutants, and understand physicochemical features associated with a variant prone to 
pathogenic misfolding. Propellers do not fall into the traditional paradigm for globular 
proteins, namely propellers do not possess a hydrophobic core. Thus, they are both more 
difficult than others to accurately predict by sequence,193 and folding pathways are not well 
understood. Finally, the location of P1 and P3 (see Chapter 3) within the innermost two 
strands of opposing Blades B and D (Figure 5.2) explains why fibrillization does not 





5.4.1 Protein Expression, Purification and Characterization  
Myoc-OLF variants T353I, R422C, S425P, Y473C, V329M and T293K were 
generated by site-directed mutagenesis (QuikChange Lightening kit, Stratagene), verified 
by DNA sequencing (MWG Operon), expressed, purified and Tms calculated as the 
midpoint of unfolding using differential scanning fluorimetry, as described previously in 



































CHAPTER 6  




 Despite the obvious importance of OLF domains in biology and disease, their 
functions remain unknown. OLF domain containing proteins are expressed throughout the 
body, particularly in neuronal tissues, where they have roles in various processes such as 
neurogenesis and neural crest formation;98 and they are implicated in a range of diseases 
including cancer, attention deficit disorder and glaucoma.98 OLF domains likely have 
additional functions apart from their full-length counterparts, as myocilin and other OLF 
proteins, such as gliomedin, a protein involved in formation of the Nodes of Ranvier, and 
the photoreceptor protein, photomedin-1, are secreted as the OLF domain alone.134, 194 
Functional studies of OLF domains, however, have proven difficult, as most identified 
protein-protein interactions of OLF proteins are independent of the OLF domain, and 
knockout studies do not yield obvious phenotypes.98 Indeed, myocilin is one of the few 
disease modifiable drug targets for glaucoma, but its native function remains unknown.45  
The myoc-OLF domain structure opens new avenues for functional studies and drug 
discovery for glaucoma by providing the first opportunity to identify ligands and sites for 
protein-protein interactions in OLF domains using rational design and in silico methods.  
 The available myoc-OLF structures, in three conformations ranging from open to 
closed (see Chapter 4 Figure 4.4), were analyzed for ligand binding by experimental and 
computational methods. We compared serendipitously-bound surface ligands from our 




methods, solvent mapping195 and ligand binding.196 We further hypothesized that the 
identified glycerol within the well conserved hydrophilic cavity59 (see Chapter 4) could 
instead bind biologically relevant metabolites common to OLF domains, such as those 
that regulate or signal ECM remodeling, development, or other changes in activity in 
neurons or AH. Specifically, we explored the possibility that the glycerol site in myoc-OLF 
could be a biological site for lactate and ascorbate, which have both been identified in 
AH.197 More generally, lactate is thought to be an energy source for neurons,198, 199and 
ascorbate is needed for collagen200 and elastin201 synthesis, and may play a role in ECM 
remodeling by matrix metalloproteases.202 The presented results set the stage for more 
detailed studies to identify common and distinct ligand binding and other interacting sites 
in OLF domains.  
 
6.2 Results  
6.2.1 Evaluation of Surface Ligand Binding  
Surface bound PEG and glycerol molecules found fortuitously along the top and 
bottom face of our structures reflect sites likely to promote ligand or protein-protein 
interactions.203  First, the aforementioned PEG and glycerol molecules that correlate with 
top surface states termed open and semi-open (see Chapter 4) bind within an area termed 
the “hole” in the two structures where the hole is present (Figure 6.1, labeled #1). In 
addition, all three OLF structures have a bound PEG molecule along the bottom surface 
near the conserved loop connecting strands C-11/C-12 (Figure 6.1, labeled #4). 
Experimental solvent mapping with acetonitrile, where glutaraldehyde cross-linked 
crystals were soaked in acetonitrile before being cryo-cooled for data collection, also 




To expand the identification of so-called hot spots that contribute 
disproportionately to the binding free energy of the OLF surface,204 we first conducted 
computational solvent mapping using FTMAP.195 FTMAP uses 16 small organic 
molecules, similar to those often used for experimental solvent mapping (see Methods), 
to probe the surface of the protein for binding consensus sites. Briefly, FTMAP uses a fast 
Fourier transform scoring technique, based on protein surface shape and patterns of 
hydrophobic and polar residues, to find energetically favorable binding regions on the 
protein.204-206 FTMAP predicted binding in the hole region for the semi-open myoc-
OLF(E396D) structure, overlaying with an experimentally modeled glycerol (Figure 6.1, 
labeled #1)  In all three structures, FTMAP also identified hot spots in the nearby groove 
region along the top surface of the protein and at the bottom surface where the PEG 
molecule was found (Figure 6.1, labeled #3 and #4 respectively). Next, we compared 
FTMAP results with those of Alignment of Pockets (APoc),196 and the more rigorous, but 
unpublished, APocSim, computational algorithms by the Skolnick lab (School of Biology) 
that compare a query structure to the numerous structures of ligand bound proteins within 
the protein data bank to determine potential ligand binding pockets within the structure.196 
APoc also predicted a binding site near the top surface hole and groove region of the 
protein (Figure 6.3 a), while APocSim showed high consensus binding within the hole and 





Figure 6.1 Experimental ligands and in silico hot spot clusters. Surface 
representations of three structures from the top or bottom face view highlighting 
experimental ligands (PEG or glycerol, red) and clusters identified by FTMAP in dark blue 





Figure 6.2 Myoc-OLF E396D structure with solvent mapped acetonitrile. Acetonitrile 
is shown as purple sticks, pink lines represent aligning FTMAP predicted hot spots and 




Table 6.1 Crystallographic statistics. 
 Myoc-OLF with 
Acetonitrile 
Data collection  
   Wavelength 1.000000 
   Space group I222 
   Cell dimensions  
      a, b, c (Å) 68.806, 86.164, 86.985  
      α,β,γ ()  90, 90, 90 
   Resolution (Å) 34.4  - 2.112  
(2.187  - 2.112) 
   Rmerge 0.1121 (0.2653) 
   I/σI 19.18 (4.59) 
   Completeness (%) 92.02 (66.04) 
   Redundancy 13.2 (8.1) 
  
Refinement  
   Resolution (Å) 34.4  - 2.112 
   No. reflections 13990 (1006) 
   Rwork/ Rfree 0.1719/0.2154  
   No. atoms  
       Protein 2064 
       Ligand/ion 20 
       Water 132 
   B-factors  
       Protein 11.10 
       Ligand/ion 20.10 
       Water 28.50 
   R.m.s deviations  
       Bond lengths (Å)  0.004 
       Bond angles () 0.86 
   Ramachandran favored      









Figure 6.3 Computational ligand binging of myoc-OLF by APoc and APocSim. a. 
APoc predicted binding with binding spots shown as green spheres on myoc-OLF top 
surface representation. b. APocSim predicted binding with molecules shown as green 
sticks on myoc-OLF top down cartoon representation. APoc and APocSim evaluation 




6.2.2 Evaluation of Ligand Binding within Hydrophilic Cavity  
Within the hydrophilic cavity of myoc-OLF a glycerol was found in both structures 
where glycerol was added during cryoprotection of the crystals (see Chapter 4).59  The 
relevance of this site is supported by in silico predictions from both FTMAP195 and APoc196, 
which identify this to be a consensus binding hot spot (Figure 6.4, Table 6.2, Figure 6.5). 
APoc analysis initially predicted 15 ligand locations with 9 distinct ligands. Since ligands 
that occupy the most similar pockets to those found within myoc-OLF by APoc may offer 
insight into potential ligands for the myoc-OLF domain, we evaluated three highly scored 




by DSF. Of these, mannose is the most stabilizing (Table 6.3). While these compounds 
are not likely biologically relevant, mannose and fucose are both sugars and other sugars 
such as glucose are found within the AH.207 However mannose and fucose are also both 
osmolytes. Thus their stabilizing effects may not be due to direct binding but by the more 





Figure 6.4 Internal ligands, in silico hot spot clusters, and computational pocket 
analysis. a. View of internal binding site identified. Glycerol is shown in red and clusters 
identified by FTMAP in dark blue b. Electron density of internal glycerol (2Fo-FC) is 
contoured at 1. c. Comparison of pockets for myoc-OLF. Pockets are colored individually.  





Table 6.2 Summary of computational analysis and observed ligand binding sites. 





















































FTMAP cluster is indicated by X. Overlapping experimental ligand, if observed, is listed 






Figure 6.5 APoc hits. Myoc-OLF structure with location of APoc hits as spheres. 





Table 6.3 ΔTm of myoc-OLF with APoc ligands. 
Additive 100mM 500mM 
Fucose 0.0 °C 1.3 °C 
Mannose 0.6 °C 3.5 °C 










6.2.3 Evaluation of Predicted Biological Ligands 
 Next, the ability of select biologically relevant identified molecules to bind myoc-
OLF was evaluated computationally using AutoDock Vina.209 The best docked location for 
citrate and glutamate coincide with the previously identified surface glycerol binding site 
(Figure 6.1, Figure 6.6, Table 6.4) and acetate, lactate and glycerol were within the internal 
glycerol site (Figure 6.2, Figure 6.6, Table 6.4). When binding was localized to the internal 
cavity, ascorbate, glutamate and lactate all exhibited more favorable calculated binding 
energies than glycerol (Table 6.5). In support of the possibility that this internal site is 







Figure 6.6 AutoDock Vina docking of biological molecules to myoc-OLF.  Top down 
and side views. Glycerols are depicted in red, acetate in purple, glutamate in orange, 




























Table 6.5 Calculated binding energies of ligands constrained to internal glycerol 
site 
Ligand 
















Figure 6.7 Thermal stability of myoc-OLF with ligands. DSF of myoc-OLF with ligands 





Table 6.6 ΔTm of myoc-OLF with predicted biological ligands. 
Additive 100mM 500mM 
Lactate 0.78 °C 4.00 °C 
Acetate 0.84 °C 3.99 °C 






 The crystal structures of myoc-OLF reveal possible ligand binding and protein 
interaction regions of the OLF domain. The combination of computational algorithms 
FTMAP and APoc and corresponding experimental validation indicate both common and 
unique binding hot spots for each of the crystallized myoc-OLF states. Regions of 
particular interest include the top surface groove of the protein and the nearby hole found 
in the open and semi-open conformations and the internal glycerol binding site. These 
experimentally and computationally identified regions may represent regions for functional 
ligand binding or protein-protein interactions. Here we showed that glutatmate, lactate, 
and ascorbate are predicted to exhibit favorable binding energies within the 
experimentally-identified internal site. Two of these ligands, along with other 
computationally predicted sugar-based ligands from APoc analysis, thermally stabilize 
myoc-OLF.  The ligands found or predicted to occupy these binding spots may shed light 
on the functional role of myocilin, and OLF domains in general. They may also provide 
scaffolds for molecules with potential to protect myoc-OLF from aggregation and thus 
mitigate the pathogenic outcome of myocilin glaucoma. Further investigations utilizing 
ligands such as glutamate and lactate, which are present in both AH and in neuronal tissue 












6.4.1 Computational Ligand Binding 
 ApoC196 calculations were completed on the myoc-OLF crystal structure by 
Ambrish Roy in the Skolnick lab at Georgia Tech. The myoc-OLF, myoc-OLF(E396D) and 
SeMet myoc-OLF(E396D) structures were submitted to the FTMAP205 server for 
evaluation of ligand binding for each structure. For docking with AutoDock Vina, the 
molecules listed in Table 6.4, which were chosen based on their similarity to glycerol and 
their occurrence in the AH or the ECM in general, were allowed to bind either the entire 
myoc-OLF structure or a region comprising of only the internal binding site. Input files were 
generated via AutoDock tools, and along with AutoDock calculations, were completed 
using default screening parameters in PyRx.214 
 
6.4.2 Protein Expression, Purification and Thermal Stability Assay   
Myoc-OLF and variants used for crystallization and thermal stability were 
expressed and purified as discussed previously in Chapters 2 and 4. Changes in thermal 
stability were assessed by DSF,105 as modified by us previously for MBP-OLF55, 64 (also 
see Chapter 2).  
 
6.4.3 Crystal Soaks, Data Collection and Refinement 
For solvent mapped crystals, crystals of myoc-OLF(E396D) (10 mg/ml in 10 mM 
HEPES, pH 7.5) were grown from 32% PEG 400, 5% PEG 3000 and 50 mM CAPSO, pH 
9.5. Crystals were cross-linked by addition of 2 µLs of 25% glutaraldehyde into the crystal 
drop 30 minutes prior to soaking in solvent as per an established protocol.215 Crystals were 
harvested and soaked in a solution of 40% acetonitrile and cryoprotectant solution, which 




cryo-cooled for data collection without additional cryo-protectant. Data were collected at 
the SER-CAT ID-22 Beamline as reported in Chapter 4. Data were integrated, scaled and 
merged using HKL2000.216 The structure was solved by molecular replacement using 
Phenix Phaser165 and the model was refined using Phenix Refine168 and Coot,166 as 
reported in Chapter 4. Data collection and refinement statistics were calculated in Phenix 







UNSUCCESSFUL TECHNIQUES FOR SOLVING EXPERIMENTAL 
PHASES AND UNSUCCESSFUL EXPERIEMENTAL LIGAND 




This appendix outlines many of the techniques employed over the two year attempt 
to solve the phases of myoc-OLF experimentally after the initial crystallization and data 
collection of wild type myoc-OLF by Dr. Susan Orwig. The crystallization of several 
variants of myoc-OLF were attempted in order to optimize the diffraction quality of the 
crystals along with various techniques for solving experimental phases for myoc-OLF and 
variants.  Also outlined here are the unsuccessful attempts for experimental ligand binding 
via crystal soaks and cocrystallization that were not highlighted in the previous chapters. 
 
A.2 Methods, Results and Conclusions 
 
A.2.1 Crystallization of Myocilin Olfactomedin Variants 
 After the initial success of wild type myoc-OLF crystallization and data collection, 
attempts were made to repeat the crystals. However these attempts did not prove 
successful even with varying parameters such as temperature, PEG size and 
concentration, buffer pH and components, and drop size, among other things. Other 




repeatable crystals. These variants are summed in Table A.1. All proteins were expressed 
and purified as previously reported in Chapter 2. Crystallization of purified protein began 
with the original myoc-OLF condition along with sparse matrix screens such as the 
Hampton HT Index screen and the Wizard Cryo I/II screens. Glycerol improved K398R 
crystal size, possibly by slowing their formation. Seeding was attempted with both K398R 
and E396D crystals but only decreased crystal size and increased the number of crystals 
in the well. Other attempts to slow crystallization and improve crystal form included E396D 
crystallization under oil and increasing reservoir to drop ratio, with no obvious 





Table A.1 Myoc-OLF variants for crystallization 
Variant Reasoning Outcome 
Myoc-OLF wild type 
 
Repeat original crystal No crystals 
K398R SNP Improve crystal form Stacked plates with smeary 
diffraction 
E396D SNP Improve crystal form Singular stacked plated (see 
Chapter 4) 
E396D / K398R 
double mutant 
 
Improve crystal form Stacked plates 




E323K/E396D E323K mutation should 
affect long loop stability 
 
Not enough monomer purified for 
crystallization 













A.2.2 Unsuccessful Techniques for Solving Experimental Phases  
After the successful crystallization of the K398R and E396D myoc-OLF SNP 
variants, several attempts at heavy metal incorporation of crystals, or of the protein before 
crystallization, were attempted. These experiments are summed below. 
A.2.2.1 Heavy Metal Soaks for Isomorphous Replacement or Anomalous Phasing 
 For heavy metal soaks, times attempted varied from 10 minutes to approximately 
72 hours. Hydrated salts of heavy metals were dissolved in water at concentrations from 
0.2 - 1 mM and 0.2 µLs of stock solution was added directly to the crystal drop. Some 
E396D crystals had β-mercaptoethanol (BME) added before the heavy metal in an attempt 
to improve incorporation of heavy metals into the protein crystal, soaks were done on 
these with and without addition of BME. Crystal soaks are summed in Table A.2. Both zinc 
and mercury metal ions were successfully incorporated and data sets were collected at 
their respective anomalous wavelength, however, the solving of phases with these metals 
was unsuccessful due to low anomalous signal and crystal pathologies including multiple 





Table A.2 Heavy metal crystal soaks. 
Metal (Salt) Myoc-OLF Variant Attempted with BME 
Pt (PtCl4K2) E396D and K398R yes 
Hg (HgCl2) K398R and E396D yes 
Zn (ZnCl2) K398R and E396D yes 
Tb (TbCl3) K398R and E396D no 
Sm 
(Sm(CH3CO2)3) 







Mn (MnCl2) E396D no 
Cu (CuCl2) E396D no 
I (KI) K398R no 
  
  
A.2.2.2  Iodophenylalanine Incorporation 
 In collaboration with the Mehl lab at Oregon State University, we attempted to 
incorporate, via molecular biology, the non-natural amino acid iodo-phenylalanine (Iodo-
Phe). Very briefly the Mehl lab has developed a method of using engineered tRNAs 
evolved to recognize a TAG stop codon to incorporate the Iodo-Phe into chosen former 
Tyr sites within the protein sequence. This procedure requires the use of cell lines that do 
not express rare codons and the incorporation of our gene into a plasmid without MBP 
fusion, which has been proven necessary for folding and solubility of myoc-OLF.64 A TAG 
site was successfully incorporated into K398R via site directed mutagenesis, however the 
changes to vector and cell type severely inhibited the expression of the myoc-OLF before 
the attempted Iodo-Phe incorporation. Since Iodo-Phe incorporation typically significantly 
reduced expression with other proteins tested in the Mehl lab, the likelihood of producing 





A.2.2.3 Incorporating Terbium into Calcium Binding Site 
 Since myoc-OLF was determined to have an internal calcium binding site (see 
Chapter 2), the potential for heavy metal incorporation into this site could be exploited for 
solving the experimental phases of myoc-OLF. Terbium has long been used as a probe 
for calcium binding,217 and its incorporation could be useful for both solving phases via 
isomorphous replacement or anomalous scattering with an accessible L-III edge of 1.65 
Å. Additionally Tb3+ incorporation could be monitored due to the fluorescent properties of 
Tb3+.   Incorporation of Tb3+ was attempted at both the growth stage, similar to SeMet, and 
after purification. During growth TbCl3 was added 30 minutes before induction with IPTG 
to cells that had reached the desired optical density in superior broth. Other than TbCl3 
addition, cell growth was as previously reported in Chapter 2. The addition of TbCl3 was 
potentially toxic to the cells or prevented induction as no purified myoc-OLF monomer was 
able to be isolated.  
 Another method for incorporating Tb3+ into myoc-OLF was through partial thermal 
unfolding of myoc-OLF in the presence of high TbCl3 concentration to compete for Ca2+ 
binding. Ca2+ could not be successfully removed by chelation with EDTA during 
purification conditions, or by high concentrations of EDTA at the slightly destabilizing pH 
of 4.6, a condition with similar secondary and tertiary spectra to apo myoc-OLF(D380A) 
(see Chapter 2).145 Partial thermal unfolding could expose the Ca2+ binding site enough 
that Tb3+ could be exchanged. 25 µM myoc-OLF(K398R) was incubated for one hour at 
various temperatures from 40 - 60 °C in the presence of 1 mM and 10 mM TbCl3 in 10 mM 
Hepes pH 7.5 buffer with no salt. After incubation, samples were dialyzed using a dialysis 
cassette overnight in 2 L Hepes pH 7.5 buffer with no salt at 4 °C with slow mixing. 
Samples were then tested for Tb3+ incorporation by unfolding protein with 2 M guanidinium 




Tb3+.218 The sample at 47.7 °C showed an increase in Tb3+ upon unfolding (Figure A.1).  
While this was repeatable at 25 µM protein, scaling up to levels of protein necessary for 
crystallization yielded mostly aggregated protein after dialysis. Therefore this method is 
only useful for small scale incorporation and not feasible for Tb3+ incorporation for 






Figure A.1 Difference emission spectra of Terbium incorporated myoc-OLF.  The 
difference fluorescence emission spectra of unfolded minus folded myoc-OLF(K398R) 
incubated with 1 mM (blue) or 10 mM (orange) TbCl3 in the presence of dipicolinic acid 



























A.2.3 Crystal Soaks of Stabilizing Compounds 
 In order to further evaluate potential ligands for myocilin OLF from this study and 
previous studies,117 co-crystal trays and soaks with ligands and myoc-OLF(E396D) were 
attempted. Ligand soaks are summarized in Table A.3. Co-crystallization attempts are 
summarized in Table A.4. All soaks were sent for data collection at the APS ID-22 
Beamline as discussed in Chapter 4, however none of the soaked ligands were evident in 




Table A.3 Crystal soaks of potential ligands. 
Potential Ligand Data Collected Structure Solved 
Ascorbate yes No 
Acetate yes No 
Glutamate yes Yes- No Ligand 
Lactate yes Yes- No Ligand 
Mannose yes Yes- No Ligand 
Fucose yes Yes- No Ligand 
Uridine yes Yes- No Ligand 
Uracil yes Yes- No Ligand 
UTP yes Yes- No Ligand 
Drug A1117 yes No 








Table A.4 Cocrystallization attempts. 
Co-Crystal Ligand Crystals Grown Data Collected Structure Solved 
Mannose Yes Yes Yes - No ligand 
Naringenin No NA NA 
Lactate No NA NA 
Acetate No NA NA 




A.2.4 Structure of the Reduced Olfactomedin Domain of Myocilin  
The structure of reduced myoc-OLF was captured crystallographically by soaking 
myoc-OLF(E396D) crystals, grown in the SeMet myoc-OLF(E396D) crystal condition, in 
BME. Purified myoc-OLF(E396D) was concentrated to 10 mg/ml, and crystals grown by 
the hanging drop method by equilibration against a solution containing 19% PEG 3350, 
0.1M Bis–Tris pH 6 and 0.1M magnesium formate. Two µLs of BME was added directly to 
the drop with crystals. Crystals were harvested into a cryoprotectant of reservoir solution 
supplemented with 15% glycerol and 5% Peg 200 before being cryo-cooled for data 
collection. There were no structural changes of the surface or internal binding regions 
compared to the SeMet myoc-OLF(E396D) structure (Figure 6.7a). However, two N-
terminal residues Gly 244 and Cys 245, which under non-reducing conditions is involved 






Figure A.2 Structure of reduced myoc-OLF. a. Overlay of reduced (green) and non-
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